OPEN ACCESS

Acute respiratory illness and return to sport: a systematic review and meta-analysis by a subgroup of the IOC consensus on 'acute respiratory illness in the athlete'

Carolette Snyders,[1,2] David B Pyne,[3] Nicola Sewry ,[1,4] James H Hull ,[5,6] Kelly Kaulback,[1,7] Martin Schwellnus [1,4]

► Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/bjsports-2021-104719).

[1]Sport, Exercise Medicine and Lifestyle Institute (SEMLI), Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa
[2]Section Sports Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa
[3]Research Institute for Sport and Exercise, Faculty of Health, University of Canberra, Canberra, Australian Capital Territory, Australia
[4]IOC Research Centre, Pretoria, Gauteng, South Africa
[5]Department of Respiratory Medicine, Royal Brompton Hospital, London, UK
[6]Institute of Sport, Exercise and Health, University College London, London, UK
[7]Department of Physiology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa

Correspondence to
Professor Martin Schwellnus, Sport, Exercise Medicine and Lifestyle Institute, University of Pretoria Faculty of Health Sciences, Pretoria 0084, South Africa; mschwell@iafrica.com

Accepted 5 November 2021
Published Online First 17 November 2021

Check for updates

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Snyders C, Pyne DB, Sewry N, *et al*. *Br J Sports Med* 2022;**56**:223–232.

ABSTRACT

Objective To determine the days until return to sport (RTS) after acute respiratory illness (ARill), frequency of time loss after ARill resulting in >1 day lost from training/competition, and symptom duration (days) of ARill in athletes.

Design Systematic review and meta-analysis.

Data sources PubMed, EBSCOhost, Web of Science, January 1990–July 2020.

Eligibility criteria Original research articles published in English on athletes/military recruits (15–65 years) with symptoms/diagnosis of an ARill and reporting any of the following: days until RTS after ARill, frequency (%) of time loss >1 day after ARill or symptom duration (days) of ARill.

Results 767 articles were identified; 54 were included (n=31 065 athletes). 4 studies reported days until RTS (range: 0–8.5 days). Frequency (%) of time loss >1 day after ARill was 20.4% (95% CI 15.3% to 25.4%). The mean symptom duration for all ARill was 7.1 days (95% CI 6.2 to 8.0). Results were similar between subgroups: pathological classification (acute respiratory infection (ARinf) vs undiagnosed ARill), anatomical classification (upper vs general ARill) or diagnostic method of ARinf (symptoms, physical examination, special investigations identifying pathogens).

Conclusions In 80% of ARill in athletes, no days were lost from training/competition. The mean duration of ARill symptoms in athletes was 7 days. Outcomes were not influenced by pathological or anatomical classification of ARill, or in ARinf diagnosed by various methods. Current data are limited, and future studies with standardised approaches to definitions, diagnostic methods and classifications of ARill are needed to obtain detailed clinical, laboratory and specific pathogen data to inform RTS.

PROSPERO registration number CRD42020160479.

INTRODUCTION

The International Olympic Committee is committed to protecting the health of the athlete.[1] Acute illness threatens athlete health and well-being, and can lead to interruption of training, withdrawal from competition and financial loss for professional athletes.[2 3] An acute illness causing delayed time to return to sport (RTS) (training and/or competition) is referred to as a 'time loss' illness.[4]

In athletes, the respiratory tract accounts for ~50% of all acute illness episodes,[5–9] and the majority of acute respiratory illnesses (ARill) in athletes are acute respiratory infections (ARinf).[6–10] The annual incidence of ARinf in the general adult population is about 2–3 episodes per year.[11] Physically active individuals typically have a lower incidence of ARinf compared with sedentary individuals, but competitive athletes may be more susceptible to ARinf, especially during periods of intense training and competition (J-shaped curve).[12] Elite athletes accustomed to very high training and competition loads may be less prone to ARinf (S-shaped curve).[13–15]

The sport and exercise medicine (SEM) physician is responsible for guiding the athlete with recent ARill to full and safe sports participation in the shortest possible time, while minimising the risk of potential medical complications. Evidence-based clinical guidelines to assist the SEM physician to decide on RTS after ARinf are lacking. RTS can be defined as 'the time (days after the onset of an injury or illness), when the ill or injured athlete can return to preillness/injury level of activity and full training and competitive sports activities, with no limitation in performance or additional risk of medical complications'.[16 17]

Symptoms of an acute illness are widely used in RTS decision making, specifically for ARinf.[18–20] Historically, athletes with localised symptoms of ARinf above the neck (eg, sore throat, rhinorrhoea or nasal congestion) were advised that exercise can resume at a low intensity for a short duration, and if exercise is well tolerated, training can continue. If symptoms are below the neck (eg, fever, myalgia or cough), the athlete was advised to rest until symptoms have resolved. These guidelines are referred to as the 'neck check'.[19] There is no scientific evidence for these guidelines and the validity of the 'neck check' as a guide for RTS has been challenged.[21] Despite the lack of data, the presence and nature (type) of regional/systemic symptoms is still a key component of most clinical decision-making guidelines for RTS following ARinf in athletes.[22–24]

Several studies report the frequency (%) of ARill that result in interruption from training/competition for >1 day (% of time loss ARill), while other studies report the duration of symptoms (days) of ARill. The frequency (%) of time loss ARill is defined as the number of ARill that resulted in time

Br J Sports Med: first published as 10.1136/bjsports-2021-104719 on 17 November 2021. Downloaded from http://bjsm.bmj.com/ on April 18, 2024 by guest. Protected by copyright.

loss >1 day from training or competition (numerator) divided by all the ARill (denominator), expressed as a %. Few studies report the actual days until RTS following ARill in athletes. Data from all these studies have not been reviewed systematically.

A systematic review with a meta-analysis was undertaken to determine the effects of ARill on RTS in athletes. Specific outcomes were days to RTS, frequency (%) of time loss ARill (ARill resulting in interruption of training/competition >1 day), and the mean duration of symptoms (days) of ARill. We also sought to determine outcomes in subgroups of ARill in athletes, based on the method used for the diagnosis of ARill, pathology (ARinf vs undiagnosed ARill), and predominant anatomical region affected [upper vs lower respiratory tract or general (upper/lower)]. The impact of ARill on other training/competition variables was also explored.

METHODS

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses[25] guidelines were used.

Study selection and eligibility criteria

Articles that fulfilled the following criteria were included:

1. Male or female participants (15–65 years), athletes at any level (recreational to elite), or military recruits engaged in training.
2. Participants with a diagnosis of ARinf (suspected or confirmed) or a mixed ARill (infective and non-infective).
3. Studies reporting any of the following variables: days lost to training/competition or RTS following an ARill, % ARill's in athletes resulting in time loss >1 day lost from training or competition (time loss ARill), the duration of symptoms of ARill or the time to recovery from ARill (days).
4. Original research journal articles.
5. Full-text articles published in English between 1 January 1990 and 31 July 2020.

Articles in non-human studies, those that reported chronic respiratory illness (including malignancy) or only non-infective ARill (eg, allergic rhinitis or asthma), review articles, expert opinions, position statements, single case-studies, conference abstracts, book chapters and commentaries were excluded.

Search strategy

PubMed, EBSCOhost and Web of Science (Core Collection) databases were searched for articles. Search terms were combined in three search strings of key terms relating to (1) ARill, (2) athletes/active individuals and (3) RTS, joined with 'AND'. The terms within the strings were joined by 'OR', and those not deemed relevant to the study question were excluded by using 'NOT' (online supplemental file 1). Search results were combined, and duplicate articles removed. Article screening and selection was conducted with the online tool CADIMA (V.2.2.1).[26] Two independent reviewers (CS and DBP) screened all articles, first by title and abstract, and then by full text. References and reviews were searched manually to identify additional articles. Disagreement among reviewers were resolved by consensus. The final selection of articles was cross-checked by two additional reviewers (MS and NS).

Data extraction

We used the term 'athletes' to combine diverse levels of sports participation and included military recruits (trainees regarded as active individuals). Participant demographics and details of data extracted for analyses from each article are summarised in online supplemental tables A and B, respectively. The following data were extracted: participants (number, age, sex), study design, type of sport or sporting event/military, level of participation (recreational/amateur/military or elite/professional/international/national), length of study surveillance, method used for the diagnosis of ARill and classification of ARill (pathological/anatomical classification), number days lost (>1) from training/competition due to ARill, duration of ARill symptoms, and the possible impact of ARill on training/competition variables. In randomised control studies, only results from control group were extracted.

Definitions and classification of subgroups of ARill

Pathological classification

Methods to diagnose an ARill, and specifically an ARinf vary substantially and include typically symptoms, findings on clinical examination and/or special investigations to identify a specific pathogen. We developed a classification system to categorise the methods to diagnose ARill in each study as follows: (1) self-reported symptoms of ARill only, (2) self-reported symptoms combined with an algorithm at least partially validated for ARinf, (3) self-reported symptoms of an ARinf reviewed by a physician, but without clinical or laboratory evaluation, (4) clinical diagnosis of an ARinf by a physician, based on history and clinical examination and (5) clinical diagnosis of ARinf by a physician confirmed by laboratory investigation to identify a specific pathogen(s) as follows: PCR testing on specimen(s), culture of an organism(s) from specimen(s) or serology (eg, rise in antibody titres). Data were extracted for each study and agreed by consensus (CS, DBP, NS and MS). Once studies were classified by the five methods of diagnosis, all ARill studies were included in one of the following main and subgroups of ARill, based on a pathological classification (table 1).

Anatomical classification

ARill (including ARinf) frequently present with both upper and lower respiratory tract symptoms/signs, and it is not always possible to clearly distinguish between these main anatomical regions when classifying ARill. A limitation of this anatomical classification is that several pathogens that cause predominantly upper ARinf can, in some cases, present with lower respiratory and/or systemic symptoms. In most studies of ARill in athletes, there is a clear distinction between upper and lower ARill, and upper ARinf (suspected or confirmed) is the most common acute illness in athletes.[6–10] Thus, from a clinical/pragmatic point of view we deemed it relevant to include an anatomical classification of ARill in the review. We classified studies into the following subgroups, based on the predominant anatomical region affected:

- Upper (ARill or ARinf): Studies where the predominant symptoms, signs, or confirmed pathology was mainly related to the upper respiratory tract (ie, above the larynx), or if the study specifically referred to athletes with upper ARill or ARinf. A few studies referred to ARinf with non-specific terms such as 'influenza', 'influenza symptoms', 'common cold', 'symptoms suggestive of influenza', 'influenza symptoms' or 'influenza like'. Studies referring to these clinical syndromes were also included in this broad anatomical classification because they are caused by pathogens that all present with predominantly upper respiratory tract symptoms.[27–30] Notably, this includes the influenza viruses, which predominantly present with upper respiratory tract

Br J Sports Med: first published as 10.1136/bjsports-2021-104719 on 17 November 2021. Downloaded from http://bjsm.bmj.com/ on April 18, 2024 by guest. Protected by copyright.

Table 1 Pathological classification (main and subgroups) of acute respiratory illness (ARill) by diagnostic method

Pathological classification			
Main group	**Subgroup**	**Methods to diagnose ARill**	**Description**
Undiagnosed ARill		► Self-reported symptoms of ARill only ► Self-reported symptoms combined with an algorithm at least partially validated for ARill ► Self-reported symptoms of an ARill reviewed by a physician, but without clinical or laboratory evaluation ► Clinical diagnosis of an ARill by a physician, based on history and clinical examination	► General symptoms of an ARill where the pathology could not be attributed specifically to an infection ► ARill studies could include illnesses that are due to either infective or non-infective causes but were not specified in the study design
ARinf	Suspected acute respiratory tract infection (ARinf)	► Self-reported symptoms combined with an algorithm at least partially validated for ARinf ► Self-reported symptoms of an ARinf reviewed by a physician, but without clinical or laboratory evaluation ► Clinical diagnosis of an ARinf by a physician, based on history and clinical examination	► General symptoms and/or physical signs suggestive of an ARinf, but where the pathology of an infection was not confirmed ► The validated questionnaires that were used including the Wisconsin Upper Respiratory Symptom Survey-21,[93] the Jackson Cold Scale,[94] or other questionnaires in which the severity of the symptoms were scored to provide a quantitative assessment,[35 95]
	Confirmed ARinf	► Clinical diagnosis of ARinf by a physician and confirmed by laboratory investigation to identify a specific pathogen as follows: PCR testing on specimen(s), culture of an organism from specimen(s), or serology (eg, rise in antibody titres)	► In some cases, a diagnosis of an ARinf caused by a specific pathogen can also be regarded as confirmed when diagnostic clinical features with a high sensitivity and specificity are present in suspected cases ► In such case there is also a high pretest probability of an ARinf (eg, a history and typical rash in an athlete where there is a confirmed viral outbreak in a travelling team or during an epidemic/pandemic)

ARinf, acute respiratory infection.

symptoms[31] and are listed as a cause of upper respiratory tract infections.[27–29]

- Lower (ARill or ARinf): Studies where the predominant symptoms or signs were below the larynx (including chest symptoms that is, cough, chest pain), or if a confirmed diagnosis specifically referred to athletes with mainly lower respiratory illness (tracheal, bronchial or lung pathology, eg, pneumonia).
- General (upper/lower) (ARill or ARinf): Studies where there were no data to clearly distinguish between predominantly upper/lower respiratory ARill. These studies could include upper, lower or both.

Quality assessment and risk of bias

The Downs and Black tool[32] was modified by removing questions pertaining to randomised controlled trials as this review only included studies using participants and outcomes. A score out of 13 (online supplemental file 2) was used to determine the quality of articles. The tool consisted of items as follow: reporting, external validity, internal validity (bias and selection bias). Each item was scored as 'yes' (score=1), 'no' (score=0) or 'undetermined' (score=0). Two reviewers (CS, DP) independently scored articles, and after discussions agreed on the final score for each article by consensus (online supplemental table C). The level of evidence was determined using the Oxford Centre for Evidence Based Medicine (2009)[33] (online supplemental table C).

Outcome measures

There were four outcome measures as follows:

Days until RTS after an ARill

The number of days to RTS after an ARill was taken as the reported days lost in training/competition due to the ARill.

Frequency (%) of time loss ARill

Another outcome variable was the frequency (%) of ARill in athletes resulting in time loss >1 day from training/competition (time loss ARill). The frequency (%) of time loss ARill is defined as the number of ARill that resulted in time loss >1 day from training or competition (numerator) divided by all the ARill (denominator), expressed as a %. This variable is reported for all ARill and in subgroups as follows: pathological classification (suspected ARinf vs undiagnosed ARill), and anatomical classification (upper ARill/ARinf vs general (upper/lower) ARill).

Duration of symptoms of ARill (days)

The mean duration of symptoms (days) of ARill in athletes is reported in the following subgroups: pathological classification (suspected ARinf vs confirmed ARinf vs undiagnosed ARill), and methods to diagnose ARinf (physician diagnosed with confirmed PCR/special investigation(s) vs physician diagnosis by history and clinical examination vs self-reported symptoms with algorithm). In studies reporting a specific causative pathogen for ARinf, the duration of symptoms for the common pathogens is reported (where available).

The effect of ARill on other training/competition variables

Studies reporting on the effect of an ARill on other training/competition variables were also reviewed. Variables included % of ARill resulting in training modification for example, training reduction/discontinuation and illness burden of ARill (illness episode resulting in the inability of player to participate fully in training/competition).[34]

Data synthesis and statistical analysis

Qualitative synthesis was performed on all 54 included articles that met the criteria for the outcome variables: days to RTS, frequency of time loss ARill, and duration of ARill symptoms. Qualitative synthesis was also performed on other training/competition variables. The frequency (%) of time loss ARill and mean duration of symptoms (days) of ARill were estimated using a DerSimonian-Laird Binary random effects model to account for heterogeneity in the cohorts (eg, differences in method of diagnosis, level of athlete) and weighting of studies. Heterogeneity was measured using I^2 statistics. For frequency, analyses of

Br J Sports Med: first published as 10.1136/bjsports-2021-104719 on 17 November 2021. Downloaded from http://bjsm.bmj.com/ on April 18, 2024 by guest. Protected by copyright.



Figure 1 Study selection flow diagram.

the subcategories of pathological and anatomical classifications of ARill were performed. For duration of symptoms, subgroup analyses for pathological classification and by methods to diagnose ARinf were performed. Differences between subgroups were determined by comparing 95% CIs. Forest plots illustrate the results. All meta-analyses were conducted using Open Meta-Analyst. Publication bias statistics including Egger tests and funnel plots for each analysis are presented (online supplemental file 3) and were analysed using ProMeta V.3. A significance level of 0.05 was accepted, and all statistical tests were two tailed.

RESULTS

Study selection

Electronic database searches identified 767 articles. After duplicates/non-eligible articles were excluded, 68 remained and 54 met the inclusion criteria for analysis of data. Reasons for exclusion at each stage of the selection process are outlined (figure 1).

Study characteristics

Data were extracted from the 54 articles[8 9 34–85] (online supplemental table A). These studies included 31 065 athletes (including military recruits), 10 706 days of surveillance, and a sex distribution of 67% males and 33% females. No articles specifically reported the days until RTS after ARill. Four studies reporting the number of days lost in training/competition due to ARill were included in the review, but not the meta-analysis given the small number and heterogeneity in reporting of the results. Eleven articles were included in the analysis of the frequency of time loss ARill, and 29 articles were included in the quantitative synthesis of duration of symptoms of ARill.

Level of evidence and quality assessment

The Oxford Level of Evidence for articles included in this review ranged from 1b to 3b (online supplemental table C). The modified Downs and Black quality assessment of the articles resulted in a total score ranging from a minimum score of 7 (fair) to the highest score of 13 (excellent) (online supplemental table C).

Days until RTS

The number of training/competition days lost due to ARill as a proxy for days until RTS was determined from data in four articles.[42 56 58 68] Training/competition days lost due to upper ARinf varied as follows: 1.7±2.3 days[56] and 3.5±5.0 days of training lost.[68] Only one study[58] reported the training/competition days lost due to lower ARinf (mean of 2.5 days per illness episode). In one study,[42] days lost were reported in two subgroups: upper ARinf and ARinf with multiple systemic symptoms (including muscle or joint pain, vomiting, diarrhoea and productive cough). In the upper ARinf subgroup, 0 days were lost, while in the systemic ARinf subgroup, up to 7 training/competition days were lost.[42] In two other studies,[72 73] total training/competition days lost due to ARill, accounted for 60%–63% of total days with all illnesses.

Frequency (%) of time loss ARill

There were 11 unique studies[8 9 36 41–45 58 62 73] reporting the frequency of time loss ARill. These studies included 18 730 participants over 1966 surveillance days. The estimated pooled % (95% CI) of all time loss ARill (>1 day) was 20.4% (15.3% to 25.4%) (I^2=69.6%) (figure 2).

The estimated pooled % of time loss ARill was similar for suspected ARinf (17.9%; 11.8–23.9) and undiagnosed ARill (21.6%; 13.6–29.7) (I^2=69.6%) as depicted in figure 3.

The number of studies distinguishing between upper and lower ARill were too few to include in the meta-analysis on % of time loss ARill. The estimated pooled % time loss ARill was similar for studies referring specifically to upper ARill (18.4%;



Figure 2 Frequency (%) of all time loss ARill (>1 day). The diamond shape represents the point estimate and CIs when an average is indicated for all the individual studies are combined. Proportions are reported as %. ARill, acute respiratory illness; Ev, event=number of time loss ARill, Trt, treatment=total number of ARill.

Br J Sports Med: first published as 10.1136/bjsports-2021-104719 on 17 November 2021. Downloaded from http://bjsm.bmj.com/ on April 18, 2024 by guest. Protected by copyright.



Figure 3 Frequency (%) of time loss acute respiratory illness (ARill) (>1 day) by pathological classification: suspected acute respiratory infection (ARinf), undiagnosed ARill. The diamond shape represents the point estimate and 95% CIs when an average is indicated for all the individual studies are combined. Proportions are reported as %. Ev, event=number of time loss ARill, Trt, treatment=total number of ARill.

10.7–26.1) when compared with studies where no distinction could be made based on the anatomical classification of ARill, that is, general (upper/lower) ARill (21.3%; 14.1–28.5) (I^2=72.3%). Studies in these two groups (upper vs general) were not combined and deemed mutually exclusive (online supplemental figure 1). There was no significant publication bias to note in the frequency analysis (online supplemental file 3).

Duration of symptoms (days) of ARill

There were 29 unique studies[35 37–39 46–57 59–61 63–71 82] that reported the duration of symptoms of ARill involving 1428 participants over 6212 surveillance days. Duration of symptoms in one study, could not be included in this analysis because of bias—as only participants with symptoms >72 hours (3 days) were included.[74] The estimated pooled mean (95% CI) duration of symptoms for all ARill was 7.1 (6.2 to 8.0) days.

The duration of symptoms in subgroups of ARill by pathological classification (undiagnosed ARill, suspected ARinf or confirmed ARinf) is shown in figure 4. In one study reporting ARinf, the population included both athletes and sedentary controls.[66] We included this study in the meta-analysis on symptom duration because the majority of ARinf (28/37=76%) were reported in athletes.

The estimated pooled mean (95% CI) duration of symptoms (days) of ARill of subgroups by pathological classification was similar for undiagnosed ARill (6.8: 4.8 to 8.7), suspected ARinf (7.0: 6.0 to 8.0) and confirmed ARinf (8.3: 6.2 to 10.3) (I^2=99.2%).

The duration of symptoms (days) of suspected ARinf (diagnosed by self-reported symptoms with algorithm and checklist) vs suspected ARinf (physician diagnosed by history and clinical examination) versus confirmed ARinf (physician diagnosis with pathology confirmed by PCR, culture or serology) are shown in figure 5.

The estimated pooled mean (95% CI) duration of symptoms (days) of ARinf by method of diagnosis was 7.2 days (6.3 to 8.2) and for individual subgroups were as follows: suspected ARinf diagnosed by self-reported symptoms with algorithm and checklist (6.7; 5.7 to 7.8), suspected ARinf diagnosed by a physician on history and clinical examination (8.0; 4.7 to 11.3) and ARinf confirmed by laboratory investigation(s) using PCR, culture or serology tests (8.3: 6.2 to 10.3) (I^2=99.3%).

The duration of symptoms in athletes with confirmed ARinf was only reported in three studies.[64 66 67] In two prospective studies over several months,[66 67] a pathogen could only be identified in ~30% of ARinf. In athletes with confirmed ARinf, symptom severity and functional impairment were most severe on day 3 and 4 of illness.[66] Rhinovirus was the most common pathogen in both studies. Time loss days were not reported in these two studies. In the third study[64] of 44 athletes participating in the Winter Olympic Games, 20 athletes presented with symptoms of the 'common cold'. A pathogen was identified in 75% of cases, and the most common pathogens causing ARinf were respiratory syncytial virus A (RSV A) followed by metapneumovirus with a mean duration of symptoms of 8.7 days and 4.0 days, respectively. Both these viruses appeared in clusters within a team travelling and living together during the Games. The next most common pathogens causing ARinf were coronaviruses 229E and OC43, each with a mean duration of symptoms of 13.5 and 18.0 days, respectively. In this study, one athlete lost time during a competition on 1 day due to an ARinf. There was significant publication bias to note in the symptom duration analysis (online supplemental file 3).

Other outcome measures

The effect of ARill on other training/competition variables

In six studies,[34 38 52 56 67 68] the effect of ARill on selected training/competition variables was reported but variables were not standardised. The main observations from these studies were as follows: 42%–70% of participants[52 56] reported that ARill negatively affected or impaired training, 14%–19% of athletes[38 67] reported reduced training volume or intensity after ARill, weekly training load was reduced by 24% in athletes[52] after ARill, training was modified in up to 50% of athletes[67] after ARill, up to 31% of elite athletes[67] ceased all training during the acute phase of their ARill, and in endurance athletes, training was reduced for 3.4±5.1 days.[68] In one study over a 4-year period, 3.2 absence days were recorded per 1000 player-days.[34]

DISCUSSION

There are several important outcomes of this systematic review and meta-analysis. The first observation is that accurate data detailing the actual number of days to RTS after ARill in athletes are very limited. Second, from the best available data,

Br J Sports Med: first published as 10.1136/bjsports-2021-104719 on 17 November 2021. Downloaded from http://bjsm.bmj.com/ on April 18, 2024 by guest. Protected by copyright.



Figure 4 The duration of symptoms (days) of subgroups of acute respiratory illness (ARill) by pathological classification: undiagnosed ARill, suspected ARinf or confirmed acute respiratory infection (ARinf). The diamond shape represents the point estimate and 95% CIs when an average is indicated for all the individual studies are combined.

approximately one in five ARill in athletes result in time loss from training/competition. Third, the estimated pooled mean duration of symptoms of ARill in athletes is 7 days. Finally, for other outcome variables related to the effect of ARill on training/competition, data are very limited, but it appears that ARill negatively affects training.

Days until RTS after an ARill

Few studies report days lost due to ARill in athletes, duration, and types of symptoms, and the reason for time loss was not verified (due to the illness or on advice from medical or coaching staff not to train while ill). The number of training/competition days lost due to suspected upper ARinf was reported in only four studies, and varied between 0 and 8.5 days.[42 56 58 68] In only one study on lower ARinf, four episodes of illness resulted in a mean of 2.5 days lost per illness.[58] Limitations of these studies are that the causative pathogen was not confirmed and the severity of infection not reported. It is likely that days until RTS after an ARinf will depend on the causative pathogen and severity of illness, as some pathogens mostly cause mild disease affecting a localised area of the respiratory tract, while others are associated with regional/systemic effects, including multiorgan involvement (moderate to severe disease). This assertion is supported by data from two recent studies on return to training (sport) after ARinf in athletes.[86 87] Both these studies could not be included in the systematic review because they fell outside the time frame (dates) of the inclusion criteria. In the first of these studies days-until-return-to-play (sport) for subcategories of ARill were reported in rugby players over five seasons (102 738 player days). ARinf resulted in significantly more days to RTS per single illness compared with non-infective ARill ($p<0.001$) (days to RTS ratio: 10.4; 95% CI 4.3 to 25.3). Lower ARinf resulted in the highest number of days to RTS per single illness followed by influenza-like illness.[86] In a second study of 84 athletes with recent ARinf, athletes with confirmed COVID-19 (n=45) had more severe disease (greater number, more severe and more prolonged symptoms), and the median days until RTS was three times longer than the subgroup with other ARinf (30 days vs 10 days).[87] In summary, there are too few data to make firm conclusions or recommendations on days until RTS after ARill or ARinf. Limited data show that days until RTS after ARinf in athletes varied from 0 to 30 days and is likely dependent on multiple factors including the definition of RTS, type of sport, individual athlete factors (susceptibility to ARinf, presence of comorbidities, immune response), the specific pathogen and the severity of the ARinf by pathology (localised upper vs regional lower ARinf vs ARinf with multiorgan involvement). More studies are needed and in future we recommend accurate recording and reporting of days until RTS, general medical history including comorbidities, symptoms (type, duration and severity) and clinical signs, evidence of regional or systemic (multiorgan) involvement and laboratory confirmation of specific pathogens.

Br J Sports Med: first published as 10.1136/bjsports-2021-104719 on 17 November 2021. Downloaded from http://bjsm.bmj.com/ on April 18, 2024 by guest. Protected by copyright.



Figure 5 The duration of symptoms (days) of suspected and confirmed ARinf by method of diagnosis. The diamond shape represents the point estimate and 95% CIs when an average is indicated for all the individual studies are combined. ARinf, acute respiratory infection

Frequency (%) of time loss ARI's

There were significant limitations in the methods used in studies included in this analysis: in some studies, the decision on time loss was estimated by the physician at the time of initial presentation and therefore not confirmed, in most cases the specific diagnosis and the causative pathogen was not confirmed, and in several studies the predominant anatomical area (upper or lower respiratory tract) affected by the ARill/ARinf was not clear. The main observation is that the % of time loss ARill (illness episodes resulting in time loss >1 day from training or competition) is low (20%) and accordingly, by inference, that the large majority (ie, 80%) of ARill are not severe, because they are associated with no time loss. The % of time loss ARill was similar in subgroups based on the pathological and anatomical classification (suspected ARinf 17.9%; undiagnosed ARill 21.6%; upper ARill 18.4%; general (upper/lower) ARill 21.3%). Although the low % of time loss ARill indicates that most ARill are not severe, there are data from other studies that clearly show a significant burden (a measure of both severity and incidence) of acute illness in athletes, particularly ARill/ARinf.[40 73 88] Future studies in this area are needed, addressing these limitations.

Duration of symptoms of ARill (days)

The mean symptom duration of any ARill in athletes was 7 days. The duration of symptoms of ARill was similar in subgroups based on the method used to diagnose ARinf: suspected ARinf diagnosed by self-reported symptoms with algorithm and checklist (6.7 days), suspected ARinf diagnosed by a physician on history/clinical examination (8.0 days) and confirmed ARinf by laboratory investigations (8.3 days). The duration of symptoms results must be interpreted with caution due to the large heterogeneity in data (I^2 >99%). In two studies, the pathogen could only be identified in ~30% of ARinf[66 67] and the most common pathogen in these studies was rhinovirus. This is also the most common pathogen causing ARinf in the general population.[89 90] A study[64] on Finnish athletes participating in the 2018 Winter Olympic Games, identified the causative pathogen in 75% of cases of ARill. The pathogens occurred in clusters of athletes travelling and living together and this might differ from the normal distribution of pathogen occurrence. In one study,[67] participants with confirmed upper ARinf the duration of symptoms was 6.8±3.8 days. In suspected ARinf (PCR/culture negative but abnormal full blood count) the duration was 6.1±3.4 days, and in the ARill subgroup (negative PCR and normal laboratory investigations) the duration of symptoms was 7.5±3.4 days. In our review, data on duration of symptoms in athletes with confirmed ARinf were, therefore, limited to a few specific pathogens that cause ARinf: rhinovirus, RSV or coronaviruses (229E and OC43).[64 66 67]

A further limitation in all the studies documenting symptoms is that the duration of specific or regional symptoms of ARill were not reported. To distinguish between symptoms is important in clinical RTS decision making[87] for example, rhinorrhoea (localised) as the only symptom may not prevent RTS, while the presence of chest pain (regional) or generalised myalgia (systemic) might delay RTS. There are data from three recently published studies (not included in the systematic review as they were published outside the time frame) documenting symptom duration in athletes infected with the specific pathogen (SARS-CoV-2) causing COVID-19. In a case series of 90 athletes with confirmed COVID-19, 23% were asymptomatic and 77% mildly symptomatic. The mean (±SD) duration of symptoms in the mildly symptomatic subgroup was 9±14 days.[91] In another study, symptoms of 'mild' COVID-19 lasted <1 week in a group of 15 symptomatic football players.[92] In the third study, individual and regional symptom duration was reported in 84 athletes with

Br J Sports Med: first published as 10.1136/bjsports-2021-104719 on 17 November 2021. Downloaded from http://bjsm.bmj.com/ on April 18, 2024 by guest. Protected by copyright.

ARinf (45 confirmed COVID-19, and 30 suspected ARinf).[87] This is the first study to report duration of specific individual symptoms in athletes with ARinf. For all the athletes with ARinf (n=84) the duration (median days) of symptoms was: localised (nose and throat) symptoms (9–10 days), regional (chest and neck) symptoms (14 days), and systemic symptoms (11 days). In this study, specific individual symptoms, and a particular symptom cluster, were associated with more prolonged return to training.[87] This symptom cluster also included symptoms 'above the neck' such as headache and altered/loss sense of smell. These symptoms were, together with 'excessive fatigue' and 'fever/chills' significantly related to prolonged return to training. These early data do not support the 'neck check' as a clinical tool for RTS decision making. In future studies, we recommend accurate recording and reporting of the duration and severity of each specific symptom, regional symptoms (such as localised, regional or systemic symptoms), as well as the specific pathogen causing an ARinf.

The effect of ARill on other training/competition variables

The effect of ARill on training could not be analysed due to small number of studies with heterogeneous reporting of results. However, from six studies[34 38 52 56 67 68] reporting on the effects of ARill on training, it is evident that an ARill potentially has a negative impact on the ability to continue with a regular training schedule. The reason/s for modification/cessation of training was not recorded and may relate to several factors including: the direct consequence of the illness process, symptoms (type, duration, severity), decrease in exercise/ sporting performance directly due to the pathology of an acute infection, and advice by medical personnel or coaching staff to modify training intensity or not to train at all.

Strengths and limitations

To our knowledge, this is the first systematic review to determine the effects of ARill on RTS in athletes. We registered the review with PROSPERO and followed a systematic approach using an online tool, CADIMA. We developed a classification system, based on methods to diagnose an ARill, and performed analyses using a pathological and anatomical classification. We believe this approach provides a more comprehensive clinical picture to inform management strategies and RTS protocols. This review has clinical importance and relevance given that ARill is the most common illness affecting athletes resulting in time loss.

The main limitations of this systematic review are related to the studies that could be included. Although we included 54 studies, these were only in the English language, and did not include recently published studies related to the COVID-19 pandemic as these fell outside the predefined time frame of the review. There is also a potential risk of publication bias that we cannot account for. Egger's tests and funnel plots indicated a higher risk for publication bias for the duration of symptoms results, compared with the prevalence of time loss data. Among studies that were included, there was inconsistency in the definition and reporting of outcome variables and heterogeneity in athletic populations studied. There was no consensus on pathological and anatomical classification and definition of ARill subgroups. We could only include a small sample of studies that reported outcome variables in subgroups (eg, confirmed ARinf). We also acknowledge that one of our outcome variables, the duration of symptoms, does not necessarily predict days until RTS after an ARill. Finally, in most studies reporting the % of time loss ARill, this was an estimated time loss ARill that physicians recorded at the time of initial diagnosis, and not necessarily verified.

The risk of publication bias was difficult to assess given poorly defined outcome variables to measure RTS and the heterogeneous methods and reporting of results. The I^2 results (I^2 >99% for duration of symptom analyses), indicates the high level of heterogeneity, and although effort was made to categories ARill in subgroups, the results were still varied. The authors acknowledge the impact this might have on the research findings. A uniform approach to the definition of variables, methods to diagnose ARill, and classification of ARill in the athletic setting is needed. In this review, we propose such classifications. We believe this framework will assist both clinicians and researchers to better characterise variables to measure RTS and their time course. This approach is important for development of evidence-based guidelines on RTS in athletes with ARill.

SUMMARY AND CLINICAL IMPLICATIONS

Respiratory illnesses are common in athletes, but to make an accurate pathological diagnosis is challenging and costly. An ARill in the athlete raises two major clinical concerns; first, the athlete and coach are concerned about the athlete's ability to train and perform, and second, the SEM physician is required to provide safe RTS guidelines for an athlete after an ARill. Such guidelines should include monitoring athletes for potential medical complications after RTS and to limit possible transmission of infective agents to team members and staff. In this systematic review and meta-analysis, we identified that~20% of ARill resulted in more than 1 day of time loss from training. The mean duration of symptoms of ARill was 7 days, regardless of pathological (infective vs undiagnosed), anatomical (upper vs general)

What is already known?

- ⇒ Acute respiratory illness (ARill) is the most common illness affecting athletes, and these are mostly acute respiratory infections (ARinf).
- ⇒ ARill can result in time loss from training and competition.
- ⇒ Return to sport (RTS) criteria after ARill in athletes are largely based on broad criteria related to symptoms 'above' or 'below' the neck.

What are the new findings?

- ⇒ The actual days to RTS after ARill is under-researched and not well documented, with large individual athlete variation.
- ⇒ The majority of ARill do not result in >1 day of time loss from training or competition.
- ⇒ The mean symptom duration of an ARill in athletes is 7 days (both ARinf and other ARill of unknown cause).
- ⇒ ARinf and ARill can have a negative impact on ability to train and compete.
- ⇒ In clinical practice and for future studies, we recommend a standardised approach to the:
  Classification and definition of ARill/ARinf.
  Method of diagnosing ARill/ARinf.
  Uniform documentation of both individual and regional symptoms of ARill/ARinf.
  Accurate recording and reporting of outcome variables (RTS, physical signs, laboratory confirmation of pathogen(s) causing ARinf).

Br J Sports Med: first published as 10.1136/bjsports-2021-104719 on 17 November 2021. Downloaded from http://bjsm.bmj.com/ on April 18, 2024 by guest. Protected by copyright.

classification or subcategories based on the method used to diagnose ARinf. In a few studies where individual and regional symptoms were recorded and a specific pathogen causing the ARinf identified, there was considerable variability in the duration of symptoms of the ARinf. Moreover, there is early evidence that discrete symptoms that are both 'above' and 'below' the neck, as well as subgroups of ARinf are associated with more prolonged time to RTS. This individual variability highlights the fact that future studies are needed where days until RTS, individual and regional symptoms (and severity of symptoms) are accurately recorded and reported in athletes with a confirmed diagnosis of ARinf (pathogen identified). This information will refine future RTS clinical decision making, which we anticipate will be highly customised and based on the individual athlete response to infection from a specific pathogen that causes ARinf.

Correction notice This article has been corrected since it published Online First. The author affiliations have been updated.

Contributors Conceptualisation: CS, DBP, NS, MS, KK and JHH. Methodology: CS, DBP, NS and MS. Writing and original draft: CS, DBP, MS and NS. Writing, review and editing: CS, DBP, NS, MS, KK and JHH.

Funding Partially supported by funding from the IOC Research Centre of South Africa.

Competing interests CS received a scholarship made possible through funding by the South African Medical Research Council through its Division of Research Capacity Development under the SAMRC Clinician Researcher Programme. The content hereof is the sole responsibility of the authors and does not necessarily represent the official views of the SAMRC.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Nicola Sewry http://orcid.org/0000-0003-1022-4780
James H Hull http://orcid.org/0000-0003-4697-1526
Martin Schwellnus http://orcid.org/0000-0003-3647-0429

REFERENCES

1 Rogge J. An ounce of prevention? *Br J Sports Med* 2009;43:627.
2 Friman G, Wesslén L. Infections and exercise in high-performance athletes. *Immunol Cell Biol* 2000;78:510–22.
3 Weidner TG, Sevier TL, Sport STL. Sport, exercise, and the common cold. *J Athl Train* 1996;31:154–9.
4 Palmer-Green D, Fuller C, Jaques R, *et al*. The Injury/Illness performance project (IIPP): a novel epidemiological approach for recording the consequences of sports injuries and illnesses. *J Sports Med* 2013;2013:1–9.
5 Engebretsen L, Steffen K, Alonso JM, *et al*. Sports injuries and illnesses during the winter Olympic Games 2010. *Br J Sports Med* 2010;44:772–80.
6 Mountjoy M, Junge A, Alonso JM, *et al*. Sports injuries and illnesses in the 2009 FINA world Championships (Aquatics). *Br J Sports Med* 2010;44:522–7.
7 Dvorak J, Junge A, Derman W, *et al*. Injuries and illnesses of football players during the 2010 FIFA World cup. *Br J Sports Med* 2011;45:626–30.
8 Schwellnus M, Derman W, Page T, *et al*. Illness during the 2010 Super 14 Rugby Union tournament - a prospective study involving 22 676 player days. *Br J Sports Med* 2012;46:499–504.
9 Soligard T, Steffen K, Palmer D, *et al*. Sports injury and illness incidence in the Rio de Janeiro 2016 Olympic summer games: a prospective study of 11274 athletes from 207 countries. *Br J Sports Med* 2017;51:1265–71.
10 Engebretsen L, Soligard T, Steffen K, *et al*. Sports injuries and illnesses during the London summer Olympic Games 2012. *Br J Sports Med* 2013;47:407–14.
11 Barrett B, Brown R, Mundt M, *et al*. The Wisconsin upper respiratory symptom survey is responsive, reliable, and valid. *J Clin Epidemiol* 2005;58:609–17.
12 Nieman DC, Exercise NDC. Exercise, upper respiratory tract infection, and the immune system. *Med Sci Sports Exerc* 1994;26:128–39.
13 Malm C. Susceptibility to infections in elite athletes: the S-curve. *Scand J Med Sci Sports* 2006;16:4–6.
14 Schwellnus M, Soligard T, Alonso J-M, *et al*. How much is too much? (Part 2) International Olympic Committee consensus statement on load in sport and risk of illness. *Br J Sports Med* 2016;50:1043–52.
15 Veugelers KR, Young WB, Fahrner B, *et al*. Different methods of training load quantification and their relationship to injury and illness in elite Australian football. *J Sci Med Sport* 2016;19:24–8.
16 van der Horst N, van de Hoef S, Reurink G, *et al*. Return to play after hamstring injuries: a qualitative systematic review of definitions and criteria. *Sports Med* 2016;46:899–912.
17 Habets B, van den Broek AG, Huisstede BMA, *et al*. Return to sport in athletes with Midportion Achilles tendinopathy: a qualitative systematic review regarding definitions and criteria. *Sports Med* 2018;48:705–23.
18 Scharhag J, Meyer T. Return to play after acute infectious disease in football players. *J Sports Sci* 2014;32:1237–42.
19 Metz JP. Upper respiratory tract infections: who plays, who SITS? *Curr Sports Med Rep* 2003;2:84–90.
20 Page CL, Diehl JJ. Upper respiratory tract infections in athletes. *Clin Sports Med* 2007;26:345–59.
21 Hull JH, Loosemore M, Schwellnus M. Respiratory health in athletes: facing the COVID-19 challenge. *Lancet Respir Med* 2020;8:557–8.
22 Ahmadinejad Z, Alijani N, Mansori S, *et al*. Common sports-related infections: a review on clinical pictures, management and time to return to sports. *Asian J Sports Med* 2014;5:1–9.
23 Lorenc TM, Kernan MT. Lower respiratory infections and potential complications in athletes. *Curr Sports Med Rep* 2006;5:80–6.
24 Smoot MK, Hosey RG. Pulmonary infections in the athlete. *Curr Sports Med Rep* 2009;8:71–5.
25 Moher D, Liberati A, Tetzlaff J, *et al*. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.
26 Kohl C, McIntosh EJ, Unger S, *et al*. Online tools supporting the conduct and reporting of systematic reviews and systematic maps: a case study on CADIMA and review of existing tools. *Environ Evid* 2018;7:8.
27 Heikkinen T, Järvinen A. The common cold. *Lancet* 2003;361:51–9.
28 Thomas M, Bomar PA. Upper Respiratory Tract Infection. [Updated 2020 Oct 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2021. Available: https://www.ncbi.nlm.nih.gov/books/NBK532961/
29 Mäkelä MJ, Puhakka T, Ruuskanen O, *et al*. Viruses and bacteria in the etiology of the common cold. *J Clin Microbiol* 1998;36:539–42.
30 Barrett B. Viral upper respiratory infection. *Integrative Medicine* 2018:170–9.
31 Carrat F, Vergu E, Ferguson NM, *et al*. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. *Am J Epidemiol* 2008;167:775–85.
32 Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *J Epidemiol Community Health* 1998;52:377–84.
33 Phillips B, Ball C, Sackett D. Oxford centre for evidence-based medicine - levels of evidence (March 2009), 2009. Available: https://wwwcebmnet/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/
34 Bjørneboe J, Kristenson K, Waldén M, *et al*. Role of illness in male professional football: not a major contributor to time loss. *Br J Sports Med* 2016;50:699–702.
35 Fricker PA, Pyne DB, Saunders PU, *et al*. Influence of training loads on patterns of illness in elite distance runners. *Clin J Sport Med* 2005;15:246–52.
36 Alonso J-M, Edouard P, Fischetto G, *et al*. Determination of future prevention strategies in elite track and field: analysis of Daegu 2011 IAAF Championships injuries and illnesses surveillance. *Br J Sports Med* 2012;46:505–14.
37 Cox AJ, Gleeson M, Pyne DB, *et al*. Respiratory symptoms and inflammatory responses to Difflam throat-spray intervention in half-marathon runners: a randomised controlled trial. *Br J Sports Med* 2010;44:127–33.
38 Cunniffe B, Griffiths H, Proctor W, *et al*. Mucosal immunity and illness incidence in elite rugby union players across a season. *Med Sci Sports Exerc* 2011;43:388–97.
39 Da Boit M, Gabriel BM, Gray P, *et al*. The effect of fish oil, vitamin D and protein on URTI incidence in young active people. *Int J Sports Med* 2015;36:426–30.
40 Derman W, Runciman P, Jordaan E, *et al*. Incidence rate and burden of illness at the Pyeongchang 2018 Paralympic winter games. *Br J Sports Med* 2019;53:1099–104.
41 Derman W, Schwellnus M, Jordaan E. Clinical characteristics of 385 illnesses of athletes with impairment reported on the WEB-IISS system during the London 2012 Paralympic Games. *PM&R* 2014;6:S23–30.

Br J Sports Med: first published as 10.1136/bjsports-2021-104719 on 17 November 2021. Downloaded from http://bjsm.bmj.com/ on April 18, 2024 by guest. Protected by copyright.

42 Dressendorfer RH, Petersen SR, Moss Lovshin SE, Lovshin SEM, *et al*. Performance enhancement with maintenance of resting immune status after intensified cycle training. *Clin J Sport Med* 2002;12:301–7.
43 Edouard P, Depiesse F, Branco P, *et al*. Analyses of Helsinki 2012 European athletics Championships injury and illness surveillance to discuss elite athletes risk factors. *Clin J Sport Med* 2014;24:409–15.
44 Edouard P, Depiesse F, Hertert P, *et al*. Injuries and illnesses during the 2011 Paris European athletics indoor Championships. *Scand J Med Sci Sports* 2013;23:e213–8.
45 Edouard P, Jacobsson J, Timpka T, *et al*. Extending in-competition athletics injury and illness surveillance with pre-participation risk factor screening: a pilot study. *Phys Ther Sport* 2015;16:98–106.
46 Fahlman MM, Engels H-J. Mucosal IgA and URTI in American College football players: a year longitudinal study. *Med Sci Sports Exerc* 2005;37:374–80.
47 Gleeson M, Bishop N, Oliveira M, *et al*. Respiratory infection risk in athletes: association with antigen-stimulated IL-10 production and salivary IgA secretion. *Scand J Med Sci Sports* 2012;22:410–7.
48 Gleeson M, Bishop NC, Oliveira M, *et al*. Daily probiotic's (Lactobacillus casei Shirota) reduction of infection incidence in athletes. *Int J Sport Nutr Exerc Metab* 2011;21:55–64.
49 Hall H, Fahlman MM, Engels HJ. Echinacea purpurea and mucosal immunity. *Int J Sports Med* 2007;28:792–7.
50 He C-S, Bishop NC, Handzlik MK, *et al*. Sex differences in upper respiratory symptoms prevalence and oral-respiratory mucosal immunity in endurance athletes. *Exerc Immunol Rev* 2014;20:8–22.
51 He C-S, Handzlik M, Muhamad A, *et al*. Influence of CMV/EBV serostatus on respiratory infection incidence during 4 months of winter training in a student cohort of endurance athletes. *Eur J Appl Physiol* 2013;113:2613–9.
52 He C-S, Handzlik M, Fraser WD, *et al*. Influence of vitamin D status on respiratory infection incidence and immune function during 4 months of winter training in endurance sport athletes. *Exerc Immunol Rev* 2013;19:86–101.
53 Ihalainen JK, Schumann M, Häkkinen K, *et al*. Mucosal immunity and upper respiratory tract symptoms in recreational endurance runners. *Appl Physiol Nutr Metab* 2016;41:96–102.
54 Kekkonen RA, Vasankari TJ, Vuorimaa T, *et al*. The effect of probiotics on respiratory infections and gastrointestinal symptoms during training in marathon runners. *Int J Sport Nutr Exerc Metab* 2007;17:352–63.
55 McFarlin BK, Carpenter KC, Davidson T, *et al*. Baker's yeast beta glucan supplementation increases salivary IgA and decreases cold/flu symptomatic days after intense exercise. *J Diet Suppl* 2013;10:171–83.
56 Michalickova D, Minic R, Dikic N, *et al*. Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. *Appl Physiol Nutr Metab* 2016;41:782–9.
57 Nehlsen-Cannarella SL, Nieman DC, Fagoaga OR, *et al*. Saliva immunoglobulins in elite women rowers. *Eur J Appl Physiol* 2000;81:222–8.
58 Orhant E, Carling C, Cox A. A three-year prospective study of illness in professional soccer players. *Res Sports Med* 2010;18:199–204.
59 Orysiak J, Witek K, Zembron-Lacny A, *et al*. Mucosal immunity and upper respiratory tract infections during a 24-week competitive season in young ice hockey players. *J Sports Sci* 2017;35:1255–63.
60 Pyne DB, McDonald WA, Gleeson M, *et al*. Mucosal immunity, respiratory illness, and competitive performance in elite swimmers. *Med Sci Sports Exerc* 2001;33:348–53.
61 Rama L, Teixeira AM, Matos A, *et al*. Changes in natural killer cell subpopulations over a winter training season in elite swimmers. *Eur J Appl Physiol* 2013;113:859–68.
62 Steffen K, Soligard T, Mountjoy M, *et al*. How do the new Olympic sports compare with the traditional Olympic sports? injury and illness at the 2018 youth Olympic summer games in Buenos Aires, Argentina. *Br J Sports Med* 2020;54:168–75.
63 Svendsen IS, Taylor IM, Tønnessen E, *et al*. Training-related and competition-related risk factors for respiratory tract and gastrointestinal infections in elite cross-country skiers. *Br J Sports Med* 2016;50:809–15.
64 Valtonen M, Waris M, Vuorinen T, *et al*. Common cold in team Finland during 2018 winter Olympic Games (PyeongChang): epidemiology, diagnosis including molecular point-of-care testing (POCT) and treatment. *Br J Sports Med* 2019;53:1093–8.
65 Cox AJ, Gleeson M, Pyne DB, *et al*. Valtrex therapy for Epstein-Barr virus reactivation and upper respiratory symptoms in elite runners. *Med Sci Sports Exerc* 2004;36:1104–10.
66 Spence L, Brown WJ, Pyne DB, *et al*. Incidence, etiology, and symptomatology of upper respiratory illness in elite athletes. *Med Sci Sports Exerc* 2007;39:577–86.
67 Cox AJ, Gleeson M, Pyne DB, *et al*. Clinical and laboratory evaluation of upper respiratory symptoms in elite athletes. *Clin J Sport Med* 2008;18:438–45.
68 Davison G, Perkins E, Jones AW, *et al*. Coldzyme® mouth spray reduces duration of upper respiratory tract infection symptoms in endurance athletes under free living conditions. *Eur J Sport Sci* 2021;21:771–80.
69 Haywood BA, Black KE, Baker D, *et al*. Probiotic supplementation reduces the duration and incidence of infections but not severity in elite rugby union players. *J Sci Med Sport* 2014;17:356–60.
70 Tiollier E, Gomez-Merino D, Burnat P, *et al*. Intense training: mucosal immunity and incidence of respiratory infections. *Eur J Appl Physiol* 2005;93:421–8.
71 West NP, Pyne DB, Cripps AW, *et al*. Lactobacillus fermentum (PCC®) supplementation and gastrointestinal and respiratory-tract illness symptoms: a randomised control trial in athletes. *Nutr J* 2011;10:30.
72 Chesson L, Deighton K, Whitehead S, *et al*. Incidence, prevalence and consequences of illness in Academy rugby League players. *J Sci Med Sport* 2020;23:1016–20.
73 Nordstrøm A, Bahr R, Talsnes O, *et al*. Prevalence and burden of health problems in male elite ice hockey players: a prospective study in the Norwegian professional League. *Orthop J Sports Med* 2020;8:2325967120902407:232596712090240.
74 Sawczuk T, Jones B, Welch M, *et al*. Prediction of upper respiratory illness using salivary immunoglobulin A in youth athletes. *Int J Sports Physiol Perform* 2021;16:511–6.
75 Laaksi I, Ruohola J-P, Tuohimaa P, *et al*. An association of serum vitamin D concentrations < 40 nmol/L with acute respiratory tract infection in young Finnish men. *Am J Clin Nutr* 2007;86:714–7.
76 Furusawa K, Tajima F, Okawa H, *et al*. The incidence of post-race symptoms of upper respiratory tract infection in wheelchair marathon racers. *Spinal Cord* 2007;45:513–7.
77 Stephenson BT, Hynes E, Leicht CA, *et al*. Brief report: training load, salivary immunoglobulin A, and illness incidence in elite Paratriathletes. *Int J Sports Physiol Perform* 2019;14:536–9.
78 Somerville V, Gill ND, Ross A, *et al*. Upper respiratory illness in different tiers of rugby Union. *Sport Sci Health* 2019;15:197–205.
79 Somerville V, Moore R, Braakhuis A. The effect of olive leaf extract on upper respiratory illness in high school athletes: a randomised control trial. *Nutrients* 2019;11:358.
80 Peters EM, Robson PJ, Kleinveldt NC, *et al*. Hematological recovery in male ultramarathon runners: the effect of variations in training load and running time. *J Sports Med Phys Fitness* 2004;44:315–21.
81 Pacque PFJ, Booth CK, Ball MJ, *et al*. The effect of an ultra-endurance running race on mucosal and humoral immune function. *J Sports Med Phys Fitness* 2007;47:496–501.
82 Nieman DC, Henson DRUA, McMAHON M, *et al*. β-Glucan, Immune Function, and Upper Respiratory Tract Infections in Athletes. *Med Sci Sports Exerc* 2008;40:1463–71.
83 Hanstad DV, Rønsen O, Andersen SS, *et al*. Fit for the fight? illnesses in the Norwegian team in the Vancouver Olympic Games. *Br J Sports Med* 2011;45:571–5.
84 Henson D, Nieman D, Davis JM, *et al*. Post-160-km race illness rates and decreases in granulocyte respiratory burst and salivary IgA output are not countered by quercetin ingestion. *Int J Sports Med* 2008;29:856–63.
85 Cox AJ, Pyne DB, Saunders PU, *et al*. Oral administration of the probiotic Lactobacillus fermentum VRI-003 and mucosal immunity in endurance athletes. *Br J Sports Med* 2010;44:222–6.
86 Jansen van Rensburg A, Janse van Rensburg DCC, Schwellnus MP, *et al*. Days until return-to-play differ for sub-categories of acute respiratory tract illness in super rugby players: a cross-sectional study over 5 seasons (102,738 player-days). *J Sci Med Sport* 2021;24:1218–23.
87 Schwellnus M, Sewry N, Snyders C, *et al*. Symptom cluster is associated with prolonged return-to-play in symptomatic athletes with acute respiratory illness (including COVID-19): a cross-sectional study—AWARE study I. *Br J Sports Med* 2021;55:1144–52.
88 Clarsen B, Rønsen O, Myklebust G, *et al*. The Oslo sports trauma research center questionnaire on health problems: a new approach to prospective monitoring of illness and injury in elite athletes. *Br J Sports Med* 2014;48:754–60.
89 Kennedy JL, Turner RB, Braciale T, *et al*. Pathogenesis of rhinovirus infection. *Curr Opin Virol* 2012;2:287–93.
90 Royston L, Tapparel C, Rhinoviruses TC. Rhinoviruses and respiratory enteroviruses: not as simple as ABC. *Viruses* 2016;8:16.
91 Cavigli L, Frascaro F, Turchini F, *et al*. A prospective study on the consequences of SARS-CoV-2 infection on the heart of young adult competitive athletes: implications for a safe return-to-play. *Int J Cardiol* 2021;336:130–6.
92 Schumacher YO, Tabben M, Hassoun K, *et al*. Resuming professional football (soccer) during the COVID-19 pandemic in a country with high infection rates: a prospective cohort study. *Br J Sports Med* 2021;55:1092–8.
93 Barrett B, Locken K, Maberry R, *et al*. The Wisconsin upper respiratory symptom survey (WURSS): a new research instrument for assessing the common cold. *J Fam Pract* 2002;51:265.
94 Jackson GG, Dowling HF, Muldoon RL. A prospective study on the consequences of SARS-CoV-2 infection on the heart of young adult competitive athletes: implications for a safe return-to-play. *Am J Public Health Nations Health* 1962;52:940–5.
95 Matthews A, Pyne D, Saunders P, *et al*. A self-reported questionnaire for quantifying illness symptoms in elite athletes. *Open Access J Sports Med* 2010;1:15–22.

Br J Sports Med: first published as 10.1136/bjsports-2021-104719 on 17 November 2021. Downloaded from http://bjsm.bmj.com/ on April 18, 2024 by guest. Protected by copyright.

Online Supplementary Figure 1
Fequency (%) time loss ARill by anatomical classification: Upper ARill vs. General (upper/lower) ARill



Online Supplementary File 1:

Specific Search Strategies

PubMed: Search: (Rhinovirus OR Parainfluenza OR Adenovirus OR coronavirus OR "human metapneumovirus" OR enterovirus OR "respiratory syncytial virus" OR "bordetella pertussis" OR "chlamydophila pneumoniae" OR "mycoplasma pneumoniae" OR Rhinitis OR influenza OR "common cold" OR flu OR sinusitis OR "rhino sinusitis" OR "acute pharyngitis" OR tonsillitis OR pharyngitis OR epiglottitis OR laryngitis OR "Haemophilus influenzae" OR "Streptococcus pneumoniae" OR "Klebsiella pneumoniae" OR "Moraxella catarrhalis" OR pneumonia OR pneumoniae OR bronchitis OR "lung disease" OR "Respiratory tract disease*" OR "Respiratory illness*" OR "Respiratory tract infection*" OR "respiration disorder*" OR "respiratory system disease*" OR "upper respiratory tract illness*" OR "upper respiratory tract disease*" OR "Lower respiratory tract illness*" OR "Lower respiratory tract disease*" OR "Viral disease*" OR "pulmonary tuberculosis" OR "laryngopharyngeal reflux" OR "supraesophageal gastric reflux" OR "non-infective acute respiratory illness" OR "air pollution" OR chemical* OR "non-infective acute respiratory disease*" OR "non-infective acute respiratory tract illness" OR "non-infective acute respiratory tract disease" OR "air pollution" OR weather OR climate OR chlorin* OR allerg* OR (inhal* AND gas*) OR "air quality" OR rhinoconjunctivitis) AND (athlete* OR sport* OR exercise* OR "athletic population" OR "active population" OR "active individual" OR military) AND ("Normalisation of organ function*" OR "Return to sport" OR "return to play" OR "return to performance" OR "return to activity" OR "Return to Sport* Activities" OR "Resumption of Sport*Activity*" OR "sport* activity resumption" OR Recovery OR "Recovery of function" OR Convalescence OR "athlete availability" OR "return to training" OR clearance) NOT (COPD OR "chronic obstructive pulmonary disease" OR cancer OR animal* OR HIV OR "human immunodeficiency virus" OR AIDS OR "acquired immunodeficiency syndrome" OR post-operative OR postoperative OR preoperative OR pre-operative OR pre-surgery OR post-surgery OR food OR radiation OR "position statement" OR "consensus statement" OR "systematic review" OR infant OR "influenza pandemic" OR "water immersion" OR concussion OR psychology* OR diabetes OR "cystic fibrosis" OR congenital OR combat OR wound OR groin OR lupus OR cryotherapy OR sleep OR bronchiectasis OR elderly OR Hajj OR "cooling kit" OR alcohol OR hyperoxia OR EMG OR war) **Filters:** Humans, English, MEDLINE, from 1990 – 2020

EbscoHost: "Human AND (Rhinovirus OR Parainfluenza OR Adenovirus OR coronavirus OR "human metapneumovirus" OR enterovirus OR "respiratory syncytial virus" OR "bordetella pertussis" OR "chlamydophila pneumoniae" OR "mycoplasma pneumoniae" OR Rhinitis OR influenza OR "common cold" OR flu OR sinusitis OR "rhino sinusitis" OR "acute pharyngitis" OR tonsillitis OR pharyngitis OR epiglottitis OR laryngitis OR "Haemophilus influenzae" OR "Streptococcus pneumoniae" OR "Klebsiella pneumoniae" OR "Moraxella catarrhalis" OR pneumonia OR pneumoniae OR bronchitis OR "lung disease" OR "Respiratory tract disease*" OR "Respiratory illness*" OR "Respiratory tract infection*" OR "respiration disorder*" OR "respiratory system disease*" OR "upper respiratory tract illness*" OR "upper respiratory tract disease*" OR "Lower respiratory tract illness*" OR "Lower respiratory tract disease*" OR "Viral disease*" OR "pulmonary tuberculosis" OR "laryngopharyngeal reflux" OR "supraesophageal gastric reflux" OR "non-infective acute respiratory illness" OR "air pollution" OR chemical* OR "non-infective acute respiratory disease*" OR "non-infective acute respiratory tract illness" OR "non-infective acute respiratory tract disease" OR "air pollution" OR weather OR climate OR chlorin* OR allerg* OR (inhal* AND gas*) OR "air quality" OR rhinoconjunctivitis) AND (athlete* OR sport* OR exercise* OR "athletic population" OR "active population" OR "active individual" OR military) AND ("Normalisation of organ function*" OR "Return to sport" OR "return to play" OR "return to performance" OR "return to activity" OR "Return to Sport* Activities" OR "Resumption of Sport*Activity*" OR "sport* activity resumption" OR Recovery OR "Recovery of function" OR Convalescence OR "athlete availability" OR "return to training" OR clearance) NOT (COPD OR "chronic obstructive pulmonary disease" OR cancer OR animal* OR HIV OR "human

immunodeficiency virus" OR AIDS OR "acquired immunodeficiency syndrome" OR post-operative OR postoperative OR preoperative OR pre-operative OR pre-surgery OR post-surgery OR food OR radiation OR "position statement" OR "consensus statement" OR "systematic review" OR infant OR "influenza pandemic" OR "water immersion" OR concussion OR psychology* OR diabetes OR "cystic fibrosis" OR congenital OR combat OR wound OR groin OR lupus OR cryotherapy OR sleep OR bronchiectasis OR elderly OR Hajj OR "cooling kit" OR alcohol OR hyperoxia OR EMG OR war) Published Date: 19910101-20200731; Document Type: Article

Web of Science: TOPIC: (Human AND (Rhinovirus OR Parainfluenza OR Adenovirus OR coronavirus OR "human metapneumovirus" OR enterovirus OR "respiratory syncytial virus" OR "bordetella pertussis" OR "chlamydophila pneumoniae" OR "mycoplasma pneumoniae" OR Rhinitis OR influenza OR "common cold" OR flu OR sinusitis OR "rhino sinusitis" OR "acute pharyngitis" OR tonsillitis OR pharyngitis OR epiglottitis OR laryngitis OR "Haemophilus influenzae" OR "Streptococcus pneumoniae" OR "Klebsiella pneumoniae" OR "Moraxella catarrhalis" OR pneumonia OR pneumoniae OR bronchitis OR "lung disease" OR "Respiratory tract disease*" OR "Respiratory illness*" OR "Respiratory tract infection*" OR "respiration disorder*" OR "respiratory system disease*" OR "upper respiratory tract illness*" OR "upper respiratory tract disease*" OR "Lower respiratory tract illness*" OR "Lower respiratory tract disease*" OR "Viral disease*" OR "pulmonary tuberculosis" OR "laryngopharyngeal reflux" OR "supraesophageal gastric reflux" OR "non-infective acute respiratory illness" OR "air pollution" OR chemical* OR "non-infective acute respiratory disease*" OR "non-infective acute respiratory tract illness" OR "non-infective acute respiratory tract disease" OR "air pollution" OR weather OR climate OR chlorin* OR allerg* OR (inhal* AND gas*) OR "air quality" OR rhinoconjunctivitis) AND (athlete* OR sport* OR exercise* OR "athletic population" OR "active population" OR "active individual" OR military) AND ("Normalisation of organ function*" OR "Return to sport" OR "return to play" OR "return to performance" OR "return to activity" OR "Return to Sport* Activities" OR "Resumption of Sport*Activity*" OR "sport* activity resumption" OR Recovery OR "Recovery of function" OR Convalescence OR "athlete availability" OR "return to training" OR clearance) NOT (COPD OR "chronic obstructive pulmonary disease" OR cancer OR animal* OR HIV OR "human immunodeficiency virus" OR AIDS OR "acquired immunodeficiency syndrome" OR post-operative OR postoperative OR preoperative OR pre-operative OR pre-surgery OR post-surgery OR food OR radiation OR "position statement" OR "consensus statement" OR "systematic review" OR infant OR "influenza pandemic" OR "water immersion" OR concussion OR psychology* OR diabetes OR "cystic fibrosis" OR congenital OR combat OR wound OR groin OR lupus OR cryotherapy OR sleep OR bronchiectasis OR elderly OR Hajj OR "cooling kit" OR alcohol OR hyperoxia OR EMG OR war))
Refined by: DOCUMENT TYPES: (ARTICLE) AND LANGUAGES: (ENGLISH)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=1990-2020

Online Supplementary File 2

Modified Downs and Black Quality Assessment Checklist[1]

Article Title and Date:		
Authors:		
	Description	Answer (circle)
REPORTING		
1	Is the hypothesis/aim/objective of the study clearly described?	Yes = 1 No = 0
2	Are the main outcomes to be measured clearly described in the Introduction or Methods section?	Yes = 1 No = 0
3	Are the characteristics of the patients included in the study clearly described?	Yes = 1 No = 0
~~4~~	~~Are the interventions of interest clearly described?~~	~~Yes = 1~~ ~~No = 0~~
~~5~~	~~Are the distributions of principal confounders in each group of subjects to be compared clearly described?~~	~~Yes = 1~~ ~~No = 0~~
6	Are the main findings of the study clearly described?	Yes = 1 No = 0
7	Does the study provide estimates of the random variability in the data for the main outcomes?	Yes = 1 No = 0
~~8~~	~~Have all important adverse events that may be a consequence of the intervention been reported?~~	~~Yes = 1~~ ~~No = 0~~
9	Have the characteristics of patients lost to follow-up been described?	Yes = 1 No = 0
10	Have actual probability values been reported (e.g. 0.035 rather than <0.05) for the main outcomes except where the probability value is less than 0.001?	Yes = 1 No = 0
EXTERNAL VALIDITY		
11	Were the subjects asked to participate in the study representative of the entire population from which they were recruited?	Yes = 1 No = 0 Unable to determine = 0
12	Were those subjects who were prepared to participate representative of the entire population from which they were recruited?	Yes = 1 No = 0 Unable to determine = 0
~~13~~	~~Were the staff, places, and facilities where the patients were treated, representative of the treatment the majority of patients receive?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
INTERNAL VALIDITY – BIAS		
~~14~~	~~Was an attempt made to blind study subjects to the intervention they have received?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
~~15~~	~~Was an attempt made to blind those measuring the main outcomes of the intervention?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
16	If any of the results of the study were based on "data dredging", was this made clear?	Yes = 1 No = 0 Unable to determine = 0
~~17~~	~~In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients, or in case-control studies, is the time period between the intervention and outcome the same for cases and controls?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~

18	Were the statistical tests used to assess the main outcomes appropriate?	Yes = 1 No = 0 Unable to determine = 0
~~19~~	~~Was compliance with the intervention/s reliable?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
20	Were the main outcome measures used accurate (valid and reliable)?	Yes = 1 No = 0 Unable to determine = 0
INTERNAL VALIDITY – CONFOUNDING (SELECTION BIAS)		
~~21~~	~~Were the patients in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited from the same population?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
~~22~~	~~Were study subjects in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited over the same period of time?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
~~23~~	~~Were study subjects randomised to intervention groups?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
~~24~~	~~Was the randomised intervention assignment concealed from both patients and health care staff until recruitment was complete and irrevocable?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
~~25~~	~~Was there adequate adjustment for confounding in the analyses from which the main findings were drawn?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
26	Were losses of patients to follow-up taken into account?	Yes = 1 No = 0 Unable to determine = 0
POWER		
~~27~~	~~Did the study have sufficient power to detect a clinically important effect where the probability value for a difference being due to chance is less than 5%?~~	~~Size of smallest intervention group~~ ~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
Assessing the quality: excellent (11-13), good (9-10), fair (7-8), and poor (≤6)[2 3]		

This checklist has been adjusted to remove the questions pertaining to RCTs, as the review used only PO (participants and outcomes).

References

1. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *Journal of Epidemiology and Community Health* 1998;52(6):377-84. doi: 10.1136/jech.52.6.377

2. Chudyk AM, Jutai JW, Petrella RJ, et al. Systematic Review of Hip Fracture Rehabilitation Practices in the Elderly. *Archives of physical medicine and rehabilitation* 2009;90(2):246-62. doi: https://doi.org/10.1016/j.apmr.2008.06.036

3. O'Connor SR, Tully MA, Ryan B, et al. Failure of a numerical quality assessment scale to identify potential risk of bias in a systematic review: a comparison study. *BMC Res Notes* 2015;8:224-24. doi: 10.1186/s13104-015-1181-1

Online Supplementary File 3

Publication statistics- Egger's test and Funnel plots

Figure 2:

Eggers test = intercept =0.47, t=0.26, p=0.802



Figure 3:

Eggers test = intercept =0.30, t=0.21, p=0.839



Figure 4

Eggers test = intercept =4.63, t=2.26, p=0.031



Figure 5:

Eggers test = intercept =5.36, t=2.12, p=0.044



Supplementary Figure 1:

Eggers test = intercept =0.45, t=0.40, p=0.699



Supplementary Table A: Summary of articles: data extraction of the demographics

Author(s), Year	Participants (n, sex)	Age of participants (years) (mean ± SD)*	Study design **	Sport / Sporting Event	Level of participation	Length of surveillance (days)
Alonso et al (2012)	n=512 (sex not recorded)	26.9 ± 4.7	Prospective	2011 IAAF World Championships	Recreational / amateur / military	9
Bjørneboe et al (2016)	n=5070 player-seasons (all male)	Not recorded	Prospective cohort	Football	Elite / professional / international / national	1 460 (1 261 367 player-days)
Chesson et al (2020)	n=17 (all male)	17.7 ± 0.7	Observational prospective cohort	Rugby (league players)	Recreational / amateur / military	175
Cox et al (2010)	n=20 (M=16, F=4)	35.2 ± 8.4	RCT	Half-marathon 21.1 km	Recreational / amateur / military	35
Cox et al (2010)[a]	n=20 (all male)	27.3 ± 6.4	RCT	Running	Recreational / amateur / military	98
Cox et al (2008)[¥]	n=70 (M=51; F=19)	19.3 ± 2.6	Prospective study	Mixed	Elite / professional / international / national	420
Cox et al (2004)	n=20 (all males)	24.6 ± 3.0	RCT	Distance Runners	Elite / professional / international / national	120
Cunniffe et al (2011)	n=31 (all male)	26.5	Prospective	Rugby	Elite / professional / international / national	336
Da Boit et al (2015)	n=17 (M=9, F=6)	28.3 ± 6.4	RCT	General	Recreational / amateur / military	112
Davison et al (2020)	n=61 (sex unknown)	39.3 ± 11.5	RCT	Endurance athletes	Recreational / amateur / military	90
Derman et al (2019)	n=567 (M=433, F=134)	32.1 ± 10.3	Prospective	Winter Paralympics	Elite / professional / international / national	12
Derman et al (2014)	n=3329 (sex not recorded)	Not recorded	Prospective	Paralympics	Elite / professional / international / national	14
Dressendorfer et al (2002)	n=9 (all males)	24.7 ± 2.1	Prospective	Mountain bike cyclists	Recreational / amateur / military	98
Edouard et al (2015)	n=528 (sex not recorded)	25.3 ± 4.2	Prospective	2013 European Athletics Indoors	Elite / professional / international / national	4

Supplementary Table A: Summary of articles: data extraction of the demographics

Edouard et al (2014)	n=1244 (sex not recorded)	Not recorded	Prospective	2012 European Athletics championships	Elite / professional / international / national	5
Edouard et al (2013)	n=440 (sex not recorded)	25.2 ± 4.0	Prospective	2011 European Athletics Indoors	Elite / professional / international / national	3
Fahlman and Engels (2005)	n=75 (all male)	20.5 ± 1.5	Prospective with athlete and control groups	American Football	Recreational / amateur / military	365
Fricker et al (2005)	n=20 (all males)	24.2 ± 3.1	Prospective	Middle-distance runners	Elite / professional / international / national	120
Furusawa et al (2007)	Racers n=21 (all male)	42.0 ± 1.74 (Mean ± SE)	Prospective cohort	Wheelchair marathon racers	Recreational / amateur	44
Gleeson et al (2012)[a]	n=80 (M=46, F=34)	22.5 ± 4.0	Prospective	Endurance-based physical activity	Recreational / amateur / military	120
Gleeson et al (2011)	n=26	25 ± 9	RCT	Endurance athletes	Recreational / amateur / military	120
Hall et al (2007)	n=14 (sex not recorded)	24.9 ± 5.8	RCT	Active adults	Recreational / amateur / military	28
Hanstad et al (2011)	n=99 (M=74, F=25)	Not recorded	Prospective	2010 Winter Olympics - Norwegian team	Elite / professional / international / national	19
Haywood et al (2014)	n=38 (all male)	24.7 ± 3.6	RCT	Rugby	Elite / professional / international / national	28
He et al (2014)	n=210 (M=147, F=63)	20.4 ± 1.9 (male) 20.5 ± 3.1 (female)	Prospective cohort	Endurance	Recreational / amateur / military	112
He et al (2013)[a]	n=31 (sex not recorded)	21 ± 2	Prospective cohort	Endurance	Recreational / amateur / military	112
He et al (2013)[b]	n=225 (sex not recorded)	21 ± 3	Prospective cohort	Endurance	Recreational / amateur / military	112
Henson et al (2008)	n=21 (M=18, F=3)	46.0 ± 2.3	RCT	Ultra marathon runner	Recreational / amateur / military	14
Ihalainen et al (2015)	n=25 (all male)	34.6 ± 1.3	Prospective cohort	Endurance	Recreational / amateur / military	84

Supplementary Table A: Summary of articles: data extraction of the demographics

Kekkonen et al (2007)	n=71 (M=63, F=8)	40 Range (23-69)	RCT	Marathon	Recreational / amateur / military	146
Laaksi et al (2007)	n=756 (all male) Control subjects (normal Vit D) n=628 (time loss recorded in this group)	Not recorded	Prospective cohort	Military	Recreational / amateur / military	184
McFarlin et al (2013)	n=35 (M=20, F=15)	35 ± 11	RCT	Marathon runners	Recreational / amateur / military	28
Michalickova et al (2016)	n=19 (M=14, F=5)	22.8 ± 2.5	RCT	Mixed	Elite / professional / international / national	98
Nehlsen-Cannarella et al (2000)	n=20 (all female)	22.6 + 0.5 (Mean ± SEM)	Prospective cohort	Rowers	Elite / professional / international / national	60
Nieman et al 2008	n=17 (all male)	25.0 ± 2.2 (Mean ± SE)	RCT	Cyclists	Recreational / amateur / military	35
Nordstrøm et al (2020)	n=225 (all male)	Mean 24 Range (17-41)	Prospective cohort study	Ice hockey	Elite / professional / international / national	210
Orhant et al (2010)¥	n=81 (all male)	Range (17–34)	Prospective cohort	Soccer	Elite / professional / international / national	1095
Orysiak et al (2017)	n=27 (all male)	16.5 ± 0.5	Prospective cohort	Ice hockey	Recreational / amateur / military	168
Pacque et al (2007)	n=17 (M=13, F=4)	41.5 ± 8.2	Prospective cohort	Ultra endurance running	Recreational / amateur / military	28
Peters et al (2004)	n=19 (all males); fast well trained runners (n=9), slow less trained runners (n=10)	35.4 ± 1.84 (fast well trained runners) 41.4 ± 2.77 (slow well trained runners) (Mean ± SEM)	Prospective cohort	Marathon runners	Recreational / amateur / military	14
Pyne et al (2001)	n=41 (M=21, F=20)	Range (15-27)	Prospective	Swimming	Elite / professional / international / national	42

Supplementary Table A: Summary of articles: data extraction of the demographics

Rama et al (2013)	n=19 (M=13, F=6)	17.2 ± 1.3 (male) 15.8 ± 0.8 (female)	Prospective cohort	Swimming	Elite / professional / international / national	203
Sawczuk et al (2020)	n=22 (M=16; F=6)	16.8 ± 0.5	Prospective longitudinal study	Mixed	Recreational / amateur / military	266
Schwellnus et al (2012)[¥]	n=259 (all male)	Not recorded	Prospective cohort	Rugby	Elite / professional / international / national	112
Soligard et al (2017)	n=11274 (M=6185, F= 5089)	Not recorded	Prospective cohort	Summer Olympics	Elite / professional / international / national	17
Somerville et al (2019)	n=12 (M=4, F=8)	16.5 ± 0.5	RCT	Hockey, football, netball	Recreational / amateur / military	63
Somerville et al (2019)[a]	Cohort 2 (school rugby) n=15; cohort 3 (school rugby) n=24, amateur n=18, total n=57 (all male)	Not recorded	Longitudinal cohort	Rugby	Recreational / amateur / military	273
Somerville et al (2019)[b]	Professional n=24 (all male)	Not recorded	Longitudinal cohort	Rugby	Elite / professional / international / national	273
Spence et al (2007)[¥]	n=63 (M=35, F=28)	22.5 ± 3.8 (elite) 25.2 ± 3.6 (recreational)	Prospective	Triathlon Cycling	Elite / professional / international / national	150
Steffen et al (2019)	n=3 984 (M=2002, F=1982)	Range (15-18)	Prospective cohort	Youth Summer Olympics	Elite / professional / international / national	13
Stephenson et al (2019)	n=7 (M=6 male, F=1)	30 ± 10	Prospective cohort	Para triathletes (mixed impairment)	Elite / professional / international / national	238
Svendsen et al (2016)	n=37 (M=22, F=17)	>18	Retrospective cohort	Cross country ski	Elite / professional / international / national	2889
Tiollier et al (2005)[¥]	n=21 (all male)	21 ± 2	Prospective cohort	Military	Recreational / amateur / military	33

Supplementary Table A: Summary of articles: data extraction of the demographics

Valtonen et al (2019¥	n=44 (M=31, F=13)	27 ± 6	Prospective observational study	Winter Olympics	Elite / professional / international / national	21
West et al (2011)	n=50 (M=33; F=17)	36.4 ± 8.9 (male) 35.6 ± 10.2 (female)	RCT	Cyclists and triathletes	Recreational / amateur / military	105

M: Males

F: Females

RCT: Randomised control trial

* All values are reported as mean + SD unless otherwise stated as range, mean ± SEM, mean ± SE or other as indicated

** In randomised control trails, only the placebo group was used for analysis

¥ Data extracted for subgroups in results table (Online Supplementary Table B)

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Author(s), Year	Classification			Outcomes						
	Method of diagnosis	**Pathological classification**	**Anatomical classification**	**Total number ARill/ARinf, number of ARill episodes or number of participants with ARill/ARinf**	**Time Loss ARill (>1 day) (n; %)**	**Days lost per ARill (days and mean ± SD)***	**Days lost (total days lost/ illness and total illnesses)**	**Symptom duration in days (mean ± SD or average) ***	**Duration of symptoms (days and number of athletes)**	**Other outcomes**
Alonso et al (2012)	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARill/ARinf	Total upper ARill n=49 Upper ARinf n=23	n=5 (5/23) 21% of upper ARinf					
Bjørneboe et al (2016)	Physician (diagnosis by history and clinical examination)	Undiagnosed ARill	General (upper/lower) ARill	ARill episodes n=1110						Illness burden 3.2 absence days/1000 player-days
Chesson et al (2020)	Self-reported symptoms only	Undiagnosed ARill	General (upper/lower) ARill	ARill n=15		Time loss (days) due to ARill n=12 days				Total days lost due to all illness n=19. Total days lost to ARill n=12 (63.2% of all time loss illnesses)
Cox et al (2010)	Self-reported symptoms with checklist and algorithm to diagnose infections	Undiagnosed ARill	Upper ARill	Upper ARill n=14				4.1 ± 3.7		

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Cox et al (2010)[a]	Self-reported symptoms with physician check (no examination)	Suspected ARinf	General (upper/lower) ARinf	ARinf episodes n=9				Mean 8 (Range not specified)	Total days all ARinf n=72	
Cox et al (2008)[a]	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARill/ARinf	All upper ARill episodes n=70 (confirmed upper ARinf pathogen identified n=21/70 (30%)				6.8 ± 3.8		50% of the athletes modified, 31% ceased all training, and 19% reduced their training volume or intensity
Cox et al (2008)[b]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Suspected upper ARinf (PCR negative but abnormal blood results) n=19/70 (27%)				6.1 ± 3.4		
Cox et al (2008)[c]	Physician (diagnosis by history and clinical examination)	Undiagnosed ARill	Upper ARill	Undiagnosed ARill n=30/70 (43%)				7.5 ± 3.4		
Cox et al (2004)	Self-reported symptoms with physician check (no examination)	Suspected ARinf	Upper ARinf	Upper ARinf n=6 in placebo month				Mean 5 Range (2-14)		

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Cunniffe et al (2011)	Self-reported symptoms with physician check (no examination)	Undiagnosed ARill	Upper ARill	Upper ARill n=123				Mean 4.7 Range (2-33)		In all ARill, 14% reported reduced activity, 8.6% felt need to go to bed
Da Boit et al (2015)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf n=8				2.79 ± 1.76		
Davison et al (2020)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Total upper ARinf n=130 episodes		Days lost 3.5 ± 5.0		10.4 ± 8.5		Reduced training 3.4 ± 5.1 (Mean ± SD)
Derman et al (2019)	Physician (diagnosis by history and clinical examination)	Undiagnosed ARill	General (upper/lower) ARill	All ARill n=28		Days lost n=9				
Derman et al (2014)	Physician (diagnosis by history and clinical examination)	Undiagnosed ARill	General (upper/lower) ARill	All ARill n=152	n=19 (19/152) 12.5% of all ARill					
Dressendorfer et al (2002)	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf n=4 (including 1 case influenza)	n=1 (influenza case) (1/5) 20% of upper ARinf	Influenza time loss days n=7 days; other upper ARinf time loss days n=0				

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Edouard et al (2015)	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf n=8	n=4 (4/8) 50% of all upper ARinf					
Edouard et al (2014)	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf n=9	n=4 (4/9) 44% of upper ARinf					Upper ARinf time loss n=4, all time-loss illness n=6 (66.7% of all time loss illnesses)
Edouard et al (2013)	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf n=8	n=1 (1/8) 12.5% of upper ARinf					
Fahlman and Engels (2005)	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf n=174				13.3 ± 3.6		
Fricker et al (2005)	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	15 athletes reported at least one episode of upper ARinf with mean number of episodes 2.5 (range 1-5)				Mean 8.3 Range (2-44)		

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Furusawa et al (2007)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Number of racers with ARinf symptoms n=8 ("throughout experiment") n=4 (post-race)						
Gleeson et al (2012)[a]	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	At least one week with upper ARinf n=50, ≥3 weeks with upper ARinf n=24				3.6 ± 1.0		
Gleeson et al (2011)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Number of ARinf episodes 2.1 ± 1.2 (Mean ± SD)				7.6 ± 3.2		
Hall et al (2007)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf n=7				8.6 ± 1.5 (Mean ± SE)		
Hanstad et al (2011)	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Total ARinf n=4; Infectious mononucleosis n=1, Upper ARinf n=3						n=1 did not compete, n=2 missed one competition, n=1 missed a relay for example

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Haywood et al (2014)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Players with upper ARinf symptoms n=19				6.7 ± 7.9		
He et al (2014)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf symptoms n=92				11.6 ± 6.8 (males) 15.5 ± 9.3 (females) Mean 13 (all)		
He et al (2013)[a]	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Number of ARinf episodes 1.0 ± 1.1 (Mean ± SD)				8.2 ± 4.0		
He et al (2013)[b]	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Participant with ≥ 1 episode of upper ARinf n=103				Mean 5 Range (5-7) (optimal Vit D n=3) Mean 8 Range (6-9) (adequate Vit D n=56) Mean 8 Range (5-14) (inadequate Vit D n=27) Mean 13 Range (10-17) (deficient Vit D n=12)		Training negatively affected in 70% of athletes with upper ARinf and training load reduced by an average of 24%.

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Henson et al (2008)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf n=5					Total sick days n=29 (for 5 ill athletes)	
Ihalainen et al (2015)	Self-reported symptoms only	Undiagnosed ARill	Upper ARill	Episodes of upper ARill symptoms n=19				11 ± 7		
Kekkonen et al (2007)	Self-reported symptoms only	Suspected ARinf	UpperARinf	Upper ARinf n=28				6.3 ± 4.3 (training group) 4.2 ± 2.2 (post-marathon group)		
Laaksi et al (2007)	Physician (diagnosis by history and clinical examination)	Suspected ARinf	General (upper/lower) ARinf			Median: 2; Q1-Q3: 0–4				
McFarlin et al (2013)	Self-reported symptoms only	Suspected ARinf	Upper ARinf					3.9 ± 0.2		
Michalickova et al (2016)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Athletes with upper ARinf n=11		Total days without training n=1.7 ± 2.3		10.6 ± 4.7	Infected days n=132 in 11 athletes	Proportion of athletes reporting impaired training 42%

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Nehlsen-Cannarella et al (2000)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf					5.2 ± 1.2 (Mean ± SE)		
Nieman et al 2008	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf n=6				3.7 ± 0.6 (Mean ± SE)		
Nordstrøm et al (2020)	Self-reported symptoms only	Undiagnosed ARill	General (upper/lower) ARill	All ARill n=151	n=53 (53/151) 35.1% of ARill		ARill total days lost n=280, total number of ARill n=151			Total days lost due to ARill n=280 (59.8% of all time loss illnesses)
Orhant et al (2010)[a]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf n=151	n=17 (17/151) 11.3% of all upper ARinf	Days lost n=34	Days lost per episode 2.0	Mean 3.1 (Range not specified)		
Orhant et al (2010)[b]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Lower ARinf	Lower ARinf n=4	n=2 (2/4) 50% of all lower ARinf	Days lost n=5	Days lost per episode 2.5	Mean 4.8 (Range not specified)		
Orysiak et al (2017)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf n=59				6.3 ± 4.6	Total symptom days n=427 in 27 athletes	

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Pacque et al (2007)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf: Pre-race n=4, post-race n=3				Average 8.5 (pre-race period) Average 6 (post-race period)	Total symptom days n=34 (pre-race) n=18 (post-race)	
Peters et al (2004)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf Fast well trained (FWT) n=5 Slow less trained (SLT) n=4				Average 4.3 (FWT) Average 3.5 (SLT)		
Pyne et al (2001)	Physician (diagnosis by history and clinical examination)	Undiagnosed ARill	General (upper/lower) ARill	ARill n=18				Median 4 Range (1-21)		
Rama et al (2013)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Episodes of upper ARinf n=31 in 19 athletes				6.7 ± 0.4		
Sawczuk et al (2020)	Self-reported symptoms only	Suspected ARinf	Upper ARinf	Upper ARinf episodes n=45				17 ± 18		
Schwellnus et al (2012)[a]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	General (upper/lower) ARinf	All ARinf n=98	Estimated time loss ARinf n=18 (18/98) 18.4% of all ARinf					

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Schwellnus et al (2012)[b]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARill/ARinf	Upper ARill n=72	Upper ARinf n=13 (13/72) 18.1% of upper ARill					
Soligard et al (2017)	Physician (diagnosis by history and clinical examination)	Undiagnosed ARill	General (upper/lower) ARill	All ARill n=292	ARill n=54 (54/292) 18.5% of all ARill					
Somerville et al (2019)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf n=12				Average 12.3		
Somerville et al (2019)[a]	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Number of subjects with ARinf in cohort 2 n=8, cohort 3 n=17, amateurs n=6				Mean upper ARinf duration per 1000 non-illness days 59.6 ± 183.2 (cohort 2) 522.1 ± 1138.8 (cohort 3) 64.3 ± 173.9 (amateurs)		
Somerville et al (2019)[b]	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Number of subject with ARinf in professional cohort n=12				Mean Upper ARinf duration per 1000 non-illness days 32.6 ± 59.7 (professionals)		

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Spence et al (2007)[a]	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	All athletes confirmed ARinf n=9				9.6 ± 2.4		Rhinovirus most common pathogen isolated. Symptom and functional impairment severity scores were higher in subjects with an infectious pathogen episode, particularly on illness days 3–4
Spence et al (2007)[b]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	All athletes suspected upper ARinf n=19				6.5 ± 3.2		
Steffen et al (2019)	Physician (diagnosis by history and clinical examination)	Undiagnosed ARill	General (upper/lower) ARill	All ARill n=168	n=37 (37/168) 22% of ARill					Time loss ARill n=37, all illness time loss n=66 (56.1% of all time loss illness)
Stephenson et al (2019)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf n=22						During 50% of upper ARinf episodes, athletes had to reduce or

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

										suspend training
Svendsen et al (2016)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	General (upper/lower) ARinf	All ARinf n=410				5 ± 4		
Tiollier et al (2005)[a]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf episodes n=16 (upper ARinf symptoms recorded n=30: rhinopharyngitis n=12/30 (40%)				7.6 ± 1.2 (Mean ± SEM)		
Tiollier et al (2005)[a]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf (tonsillitis) n=5/30 (17%)				8.2 ± 3.8 (Mean ± SEM)		
Tiollier et al (2005)[a]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf (sinusitis) n=4/30 (13%)				10.7 ± 4.8 (Mean ± SEM)		
Tiollier et al (2005)[a]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf (otitis media) n=3/30 (10%)				4.3 ± 0.9 (Mean ± SEM)		

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Tiollier et al (2005)[b]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Lower ARinf	Lower ARinf (bronchitis) n=6/30 (20%)				7.8 ± 2.3 (Mean ± SEM)		
Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	Upper ARinf (athletes with symptoms of "common cold") n=20				8.3 ± 7.8		Only one athlete lost competition on 1 day due to a respiratory infection
Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	Coronavirus 229E n=2				13.5 ± 16.3		
Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	Influenza B n=1				7.0		
Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	Respiratory syncytial virus (RSV) A n=4				8.7 ± 3.2		

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	UpperARinf	Rhinovirus n=1				2.0		
Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	Metapneumo virus n=4				4.0 ± 1.7		
Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	Coronavirus NL63 n=1				3.0		
Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	Coronavirus OC43 n=2				18.0 ± 11.3		
Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	Respiratory syncytial virus (RSV) B n=1				7.0		

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	lnfluenza A n=1				3.0		
West et al (2011)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Lower ARinf					7.4 ± 10.3 (males) 5.1 ± 14.7 (females)		

ARill: Acute respiratory illness
ARinf: Acute respiratory infection
* Values are mean ± standard deviation (SD) unless stated differently

Online Supplementary Table C: Modified Downs and Black and Oxford Level of Evidence

Author(s), Year	Modified Downs and Black (score out of 13)	Oxford Level of Evidence
Alonso et al (2012)	12	2b
Bjørneboe et al (2016)	11	1b
Chesson et al (2020)	10	1b
Cox et al (2010)	11	1b
Cox et al (2010)[a]	11	1b
Cox et al (2008)	10	2b
Cox et al (2004)	10	1b
Cunniffe et al (2011)	11	2b
Da Boit et al (2015)	11	1b
Davison et al (2020)	10	2b
Derman et al (2019)	12	2b
Derman et al (2014)	12	2b
Dressendorfer et al (2002)	9	2b
Edouard et al (2015)	13	2b
Edouard et al (2014)	12	2b
Edouard et al (2013)	12	2b
Fahlman and Engels (2005)	12	2b
Fricker et al (2005)	10	2b
Furusawa et al (2007)	9	3b
Gleeson et al (2012)[a]	10	2b
Gleeson et al (2011)	10	1b
Hall et al (2007)	10	1b
Hanstad et al (2011)	12	2b
Haywood et al (2014)	10	1b

Online Supplementary Table C: Modified Downs and Black and Oxford Level of Evidence

He et al (2014)	10	1b
He et al (2013)[a]	11	1b
He et al (2013)[b]	11	2b
Henson et al (2008)	10	1b
Ihalainen et al (2015)	10	2b
Kekkonen et al (2007)	12	1b
Laaksi et al (2007)	12	1b
McFarlin et al (2013)	10	1b
Michalickova et al (2016)	9	1b
Nehlsen-Cannarella et al (2000)	11	2b
Nieman et al 2008	7	2b
Nordstrøm et al (2020)	12	2b
Orhant et al (2010)	8	2b
Orysiak et al (2017)	11	2b
Pacque et al (2007)	12	2b
Peters et al (2004)	10	2b
Pyne et al (2001)	12	2b
Rama et al (2013)	10	3b
Sawczuk et al (2020)	10	2b
Schwellnus et al (2012)	10	2b
Soligard et al (2017)	12	2b
Somerville et al (2019)	11	2b
Somerville et al (2019)[a]	10	2b
Spence et al (2007)	10	1b
Steffen et al (2019)	11	2b
Stephenson et al (2019)	10	3b

Online Supplementary Table C: Modified Downs and Black and Oxford Level of Evidence

Svendsen et al (2016)	11	2b
Tiollier et al (2005)	10	2b
Valtonen et al (2019)	12	1b
West et al (2011)	10	1b

Online Supplementary Table C: Modified Downs and Black and Oxford Level of Evidence

		Modified Downs and Black													
Author, year	Oxford Level of Evidence	Reporting Yes=1 No=0							External validity Yes = 1 No = 0 Unable to determine= 0		Internal validity - bias Yes = 1 No = 0 Unable to determine= 0			Internal validity - confounding (selection bias) Yes = 1 No = 0 Unable to determine= 0	
		Hypothesis / aim described	Main outcomes described	Characteristics of patients described	Main findings described	Estimates of the random variability	Characteristics of patients lost to follow-up	Actual probability values	Subjects recruited representative of the entire population	Subjects participating representative of the entire population	Data dredging reported (if applicable)	Statistical tests used	Outcome measures valid/ reliable	Losses of follow up taken into account	Total
Alonso et al (2012)	2b	1	1	0	1	1	1	1	1	1	1	1	1	1	12
Bjørneboe et al (2016)	1b	1	1	0	1	1	0	1	1	1	1	1	1	1	11
Chesson et al (2020)	1b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Cox et al (2010)	1b	1	1	1	1	1	1	1	0	0	1	1	1	1	11
Cox et al (2010)a	1b	1	1	1	1	1	1	1	0	0	1	1	1	1	11
Cox et al (2008)	2b	1	1	1	1	1	1	0	0	0	1	1	1	1	10
Cox et al (2004)	1b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Cunniffe et al (2011)	1b	1	1	0	1	1	1	0	1	1	1	1	1	1	11
Da Boit et al (2015)	1b	1	1	0	1	1	1	0	1	1	1	1	1	1	11

Online Supplementary Table C: Modified Downs and Black and Oxford Level of Evidence

Davison et al (2020)	2b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Derman et al (2019)	2b	1	1	1	1	1	1	0	1	1	1	1	1	1	12
Derman et al (2014)	2b	1	1	1	1	1	1	0	1	1	1	1	1	1	12
Dressendorfer et al (2002)	2b	1	1	0	1	1	1	0	0	0	1	1	1	1	9
Edouard et al (2015)	2b	1	1	1	1	1	1	1	1	1	1	1	1	1	13
Edouard et al (2014)	2b	1	1	0	1	1	1	1	1	1	1	1	1	1	12
Edouard et al (2013)	2b	1	1	0	1	1	1	1	1	1	1	1	1	1	12
Fahlman and Engels (2005)	2b	1	1	1	0	1	1	1	1	1	1	1	1	1	12
Fricker et al (2005)	2b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Furusawa et al (2007)	3b	1	1	0	1	1	1	0	0	0	1	1	1	1	9
Gleeson et al (2012)a	2b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Gleeson et al (2011)	1b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Hall et al (2007)	1b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Hanstad et al (2011)	2b	1	1	0	1	1	1	1	1	1	1	1	1	1	12
Haywood et al (2014)	1b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
He et al (2014)	1b	1	1	1	1	1	1	1	0	0	0	1	1	1	10
He et al (2013)a	1b	1	1	1	1	1	1	1	0	0	1	1	1	1	11

Online Supplementary Table C: Modified Downs and Black and Oxford Level of Evidence

He et al (2013)b	2b	1	1	1	1	1	1	1	0	0	1	1	1	1	11
Henson et al (2008)	1b	1	1	1	1	1	0	1	0	0	1	1	1	1	10
Ihalainen et al (2015)	2b	1	1	1	1	1	1	0	0	0	1	1	1	1	10
Kekkonen et al (2007)	1b	1	1	1	1	1	1	1	0	1	1	1	1	1	12
Laaksi et al (2007)	1b	1	1	0	1	1	1	1	1	1	1	1	1	1	12
McFarlin et al (2013)	1b	1	1	1	1	1	0	1	0	0	1	1	1	1	10
Michalickova et al (2016)	1b	1	1	1	1	1	0	1	0	0	1	1	1	0	9
Nehlsen-Cannarella et al (2000)	2b	1	1	1	1	1	1	1	0	0	1	1	1	1	11
Nieman et al (2008)	2b	1	1	0	0	1	0	1	0	0	1	1	1	0	7
Nordstrøm et al (2020)	2b	1	1	1	1	1	1	0	1	1	1	1	1	1	12
Orhant et al (2010)	2b	1	1	0	1	1	0	0	1	1	1	1	0	0	8
Orysiak et al (2017)	2b	1	1	1	1	1	1	1	0	0	1	1	1	1	11
Pacque et al (2007)	2b	1	1	1	1	1	1	1	1	1	0	1	1	1	12
Peters et al (2004)	2b	1	1	1	1	1	0	1	1	1	0	1	1	0	10
Pyne et al (2001)	2b	1	1	1	1	1	1	1	1	1	0	1	1	1	12
Rama et al (2013)	3b	1	1	1	1	1	1	1	0	0	0	1	1	1	10

Online Supplementary Table C: Modified Downs and Black and Oxford Level of Evidence

Sawczuk et al (2020)	2b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Schwellnus et al (2012)	2b	1	1	0	1	1	0	0	1	1	1	1	1	1	10
Soligard et al (2017)	2b	1	1	1	1	1	1	0	1	1	1	1	1	1	12
Somerville et al (2019)	2b	1	1	1	1	1	0	0	1	1	1	1	1	1	11
Somerville et al (2019)a	2b	1	1	1	1	1	0	1	0	0	1	1	1	1	10
Spence et al (2007)	1b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Steffen et al (2019)	2b	1	1	0	1	1	1	0	1	1	1	1	1	1	11
Stephenson et al (2019)	3b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Svendsen et al (2016)	1b	1	1	1	1	1	1	1	0	0	1	1	1	1	11
Tiollier et al (2005)a	2b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Valtonen et al (2019)	1b	1	1	0	1	1	1	1	1	1	1	1	1	1	12
West et al (2011)	1b	1	1	1	1	1	1	0	0	0	1	1	1	1	10

Online Supplementary Table C: Modified Downs and Black and Oxford Level of Evidence

Online Supplementary Figure 1
Fequency (%) time loss ARill by anatomical classification: Upper ARill vs. General (upper/lower) ARill



Online Supplementary File 1:

Specific Search Strategies

PubMed: Search: (Rhinovirus OR Parainfluenza OR Adenovirus OR coronavirus OR "human metapneumovirus" OR enterovirus OR "respiratory syncytial virus" OR "bordetella pertussis" OR "chlamydophila pneumoniae" OR "mycoplasma pneumoniae" OR Rhinitis OR influenza OR "common cold" OR flu OR sinusitis OR "rhino sinusitis" OR "acute pharyngitis" OR tonsillitis OR pharyngitis OR epiglottitis OR laryngitis OR "Haemophilus influenzae" OR "Streptococcus pneumoniae" OR "Klebsiella pneumoniae" OR "Moraxella catarrhalis" OR pneumonia OR pneumoniae OR bronchitis OR "lung disease" OR "Respiratory tract disease*" OR "Respiratory illness*" OR "Respiratory tract infection*" OR "respiration disorder*" OR "respiratory system disease*" OR "upper respiratory tract illness*" OR "upper respiratory tract disease*" OR "Lower respiratory tract illness*" OR "Lower respiratory tract disease*" OR "Viral disease*" OR "pulmonary tuberculosis" OR "laryngopharyngeal reflux" OR "supraesophageal gastric reflux" OR "non-infective acute respiratory illness" OR "air pollution" OR chemical* OR "non-infective acute respiratory disease*" OR "non-infective acute respiratory tract illness" OR "non-infective acute respiratory tract disease" OR "air pollution" OR weather OR climate OR chlorin* OR allerg* OR (inhal* AND gas*) OR "air quality" OR rhinoconjunctivitis) AND (athlete* OR sport* OR exercise* OR "athletic population" OR "active population" OR "active individual" OR military) AND ("Normalisation of organ function*" OR "Return to sport" OR "return to play" OR "return to performance" OR "return to activity" OR "Return to Sport* Activities" OR "Resumption of Sport*Activity*" OR "sport* activity resumption" OR Recovery OR "Recovery of function" OR Convalescence OR "athlete availability" OR "return to training" OR clearance) NOT (COPD OR "chronic obstructive pulmonary disease" OR cancer OR animal* OR HIV OR "human immunodeficiency virus" OR AIDS OR "acquired immunodeficiency syndrome" OR post-operative OR postoperative OR preoperative OR pre-operative OR pre-surgery OR post-surgery OR food OR radiation OR "position statement" OR "consensus statement" OR "systematic review" OR infant OR "influenza pandemic" OR "water immersion" OR concussion OR psychology* OR diabetes OR "cystic fibrosis" OR congenital OR combat OR wound OR groin OR lupus OR cryotherapy OR sleep OR bronchiectasis OR elderly OR Hajj OR "cooling kit" OR alcohol OR hyperoxia OR EMG OR war) **Filters:** Humans, English, MEDLINE, from 1990 – 2020

EbscoHost: "Human AND (Rhinovirus OR Parainfluenza OR Adenovirus OR coronavirus OR "human metapneumovirus" OR enterovirus OR "respiratory syncytial virus" OR "bordetella pertussis" OR "chlamydophila pneumoniae" OR "mycoplasma pneumoniae" OR Rhinitis OR influenza OR "common cold" OR flu OR sinusitis OR "rhino sinusitis" OR "acute pharyngitis" OR tonsillitis OR pharyngitis OR epiglottitis OR laryngitis OR "Haemophilus influenzae" OR "Streptococcus pneumoniae" OR "Klebsiella pneumoniae" OR "Moraxella catarrhalis" OR pneumonia OR pneumoniae OR bronchitis OR "lung disease" OR "Respiratory tract disease*" OR "Respiratory illness*" OR "Respiratory tract infection*" OR "respiration disorder*" OR "respiratory system disease*" OR "upper respiratory tract illness*" OR "upper respiratory tract disease*" OR "Lower respiratory tract illness*" OR "Lower respiratory tract disease*" OR "Viral disease*" OR "pulmonary tuberculosis" OR "laryngopharyngeal reflux" OR "supraesophageal gastric reflux" OR "non-infective acute respiratory illness" OR "air pollution" OR chemical* OR "non-infective acute respiratory disease*" OR "non-infective acute respiratory tract illness" OR "non-infective acute respiratory tract disease" OR "air pollution" OR weather OR climate OR chlorin* OR allerg* OR (inhal* AND gas*) OR "air quality" OR rhinoconjunctivitis) AND (athlete* OR sport* OR exercise* OR "athletic population" OR "active population" OR "active individual" OR military) AND ("Normalisation of organ function*" OR "Return to sport" OR "return to play" OR "return to performance" OR "return to activity" OR "Return to Sport* Activities" OR "Resumption of Sport*Activity*" OR "sport* activity resumption" OR Recovery OR "Recovery of function" OR Convalescence OR "athlete availability" OR "return to training" OR clearance) NOT (COPD OR "chronic obstructive pulmonary disease" OR cancer OR animal* OR HIV OR "human

immunodeficiency virus" OR AIDS OR "acquired immunodeficiency syndrome" OR post-operative OR postoperative OR preoperative OR pre-operative OR pre-surgery OR post-surgery OR food OR radiation OR "position statement" OR "consensus statement" OR "systematic review" OR infant OR "influenza pandemic" OR "water immersion" OR concussion OR psychology* OR diabetes OR "cystic fibrosis" OR congenital OR combat OR wound OR groin OR lupus OR cryotherapy OR sleep OR bronchiectasis OR elderly OR Hajj OR "cooling kit" OR alcohol OR hyperoxia OR EMG OR war) Published Date: 19910101-20200731; Document Type: Article

Web of Science: TOPIC: (Human AND (Rhinovirus OR Parainfluenza OR Adenovirus OR coronavirus OR "human metapneumovirus" OR enterovirus OR "respiratory syncytial virus" OR "bordetella pertussis" OR "chlamydophila pneumoniae" OR "mycoplasma pneumoniae" OR Rhinitis OR influenza OR "common cold" OR flu OR sinusitis OR "rhino sinusitis" OR "acute pharyngitis" OR tonsillitis OR pharyngitis OR epiglottitis OR laryngitis OR "Haemophilus influenzae" OR "Streptococcus pneumoniae" OR "Klebsiella pneumoniae" OR "Moraxella catarrhalis" OR pneumonia OR pneumoniae OR bronchitis OR "lung disease" OR "Respiratory tract disease*" OR "Respiratory illness*" OR "Respiratory tract infection*" OR "respiration disorder*" OR "respiratory system disease*" OR "upper respiratory tract illness*" OR "upper respiratory tract disease*" OR "Lower respiratory tract illness*" OR "Lower respiratory tract disease*" OR "Viral disease*" OR "pulmonary tuberculosis" OR "laryngopharyngeal reflux" OR "supraesophageal gastric reflux" OR "non-infective acute respiratory illness" OR "air pollution" OR chemical* OR "non-infective acute respiratory disease*" OR "non-infective acute respiratory tract illness" OR "non-infective acute respiratory tract disease" OR "air pollution" OR weather OR climate OR chlorin* OR allerg* OR (inhal* AND gas*) OR "air quality" OR rhinoconjunctivitis) AND (athlete* OR sport* OR exercise* OR "athletic population" OR "active population" OR "active individual" OR military) AND ("Normalisation of organ function*" OR "Return to sport" OR "return to play" OR "return to performance" OR "return to activity" OR "Return to Sport* Activities" OR "Resumption of Sport*Activity*" OR "sport* activity resumption" OR Recovery OR "Recovery of function" OR Convalescence OR "athlete availability" OR "return to training" OR clearance) NOT (COPD OR "chronic obstructive pulmonary disease" OR cancer OR animal* OR HIV OR "human immunodeficiency virus" OR AIDS OR "acquired immunodeficiency syndrome" OR post-operative OR postoperative OR preoperative OR pre-operative OR pre-surgery OR post-surgery OR food OR radiation OR "position statement" OR "consensus statement" OR "systematic review" OR infant OR "influenza pandemic" OR "water immersion" OR concussion OR psychology* OR diabetes OR "cystic fibrosis" OR congenital OR combat OR wound OR groin OR lupus OR cryotherapy OR sleep OR bronchiectasis OR elderly OR Hajj OR "cooling kit" OR alcohol OR hyperoxia OR EMG OR war))
Refined by: DOCUMENT TYPES: (ARTICLE) AND LANGUAGES: (ENGLISH)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=1990-2020

Online Supplementary File 2

Modified Downs and Black Quality Assessment Checklist[1]

Article Title and Date:		
Authors:		
	Description	Answer (circle)
REPORTING		
1	Is the hypothesis/aim/objective of the study clearly described?	Yes = 1 No = 0
2	Are the main outcomes to be measured clearly described in the Introduction or Methods section?	Yes = 1 No = 0
3	Are the characteristics of the patients included in the study clearly described?	Yes = 1 No = 0
~~4~~	~~Are the interventions of interest clearly described?~~	~~Yes = 1~~ ~~No = 0~~
~~5~~	~~Are the distributions of principal confounders in each group of subjects to be compared clearly described?~~	~~Yes = 1~~ ~~No = 0~~
6	Are the main findings of the study clearly described?	Yes = 1 No = 0
7	Does the study provide estimates of the random variability in the data for the main outcomes?	Yes = 1 No = 0
~~8~~	~~Have all important adverse events that may be a consequence of the intervention been reported?~~	~~Yes = 1~~ ~~No = 0~~
9	Have the characteristics of patients lost to follow-up been described?	Yes = 1 No = 0
10	Have actual probability values been reported (e.g. 0.035 rather than <0.05) for the main outcomes except where the probability value is less than 0.001?	Yes = 1 No = 0
EXTERNAL VALIDITY		
11	Were the subjects asked to participate in the study representative of the entire population from which they were recruited?	Yes = 1 No = 0 Unable to determine = 0
12	Were those subjects who were prepared to participate representative of the entire population from which they were recruited?	Yes = 1 No = 0 Unable to determine = 0
~~13~~	~~Were the staff, places, and facilities where the patients were treated, representative of the treatment the majority of patients receive?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
INTERNAL VALIDITY – BIAS		
~~14~~	~~Was an attempt made to blind study subjects to the intervention they have received?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
~~15~~	~~Was an attempt made to blind those measuring the main outcomes of the intervention?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
16	If any of the results of the study were based on "data dredging", was this made clear?	Yes = 1 No = 0 Unable to determine = 0
~~17~~	~~In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients, or in case-control studies, is the time period between the intervention and outcome the same for cases and controls?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~

18	Were the statistical tests used to assess the main outcomes appropriate?	Yes = 1 No = 0 Unable to determine = 0
~~19~~	~~Was compliance with the intervention/s reliable?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
20	Were the main outcome measures used accurate (valid and reliable)?	Yes = 1 No = 0 Unable to determine = 0
INTERNAL VALIDITY – CONFOUNDING (SELECTION BIAS)		
~~21~~	~~Were the patients in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited from the same population?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
~~22~~	~~Were study subjects in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited over the same period of time?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
~~23~~	~~Were study subjects randomised to intervention groups?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
~~24~~	~~Was the randomised intervention assignment concealed from both patients and health care staff until recruitment was complete and irrevocable?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
~~25~~	~~Was there adequate adjustment for confounding in the analyses from which the main findings were drawn?~~	~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
26	Were losses of patients to follow-up taken into account?	Yes = 1 No = 0 Unable to determine = 0
POWER		
~~27~~	~~Did the study have sufficient power to detect a clinically important effect where the probability value for a difference being due to chance is less than 5%?~~	~~Size of smallest intervention group~~ ~~Yes = 1~~ ~~No = 0~~ ~~Unable to determine = 0~~
Assessing the quality: excellent (11-13), good (9-10), fair (7-8), and poor (≤6)[2 3]		

This checklist has been adjusted to remove the questions pertaining to RCTs, as the review used only PO (participants and outcomes).

References

1. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *Journal of Epidemiology and Community Health* 1998;52(6):377-84. doi: 10.1136/jech.52.6.377

2. Chudyk AM, Jutai JW, Petrella RJ, et al. Systematic Review of Hip Fracture Rehabilitation Practices in the Elderly. *Archives of physical medicine and rehabilitation* 2009;90(2):246-62. doi: https://doi.org/10.1016/j.apmr.2008.06.036

3. O'Connor SR, Tully MA, Ryan B, et al. Failure of a numerical quality assessment scale to identify potential risk of bias in a systematic review: a comparison study. *BMC Res Notes* 2015;8:224-24. doi: 10.1186/s13104-015-1181-1

Online Supplementary File 3

Publication statistics- Egger's test and Funnel plots

Figure 2:

Eggers test = intercept =0.47, t=0.26, p=0.802



Figure 3:

Eggers test = intercept =0.30, t=0.21, p=0.839



Figure 4

Eggers test = intercept =4.63, t=2.26, p=0.031



Figure 5:

Eggers test = intercept =5.36, t=2.12, p=0.044



Supplementary Figure 1:

Eggers test = intercept =0.45, t=0.40, p=0.699



Supplementary Table A: Summary of articles: data extraction of the demographics

Author(s), Year	Participants (n, sex)	Age of participants (years) (mean ± SD)*	Study design **	Sport / Sporting Event	Level of participation	Length of surveillance (days)
Alonso et al (2012)	n=512 (sex not recorded)	26.9 ± 4.7	Prospective	2011 IAAF World Championships	Recreational / amateur / military	9
Bjørneboe et al (2016)	n=5070 player-seasons (all male)	Not recorded	Prospective cohort	Football	Elite / professional / international / national	1 460 (1 261 367 player-days)
Chesson et al (2020)	n=17 (all male)	17.7 ± 0.7	Observational prospective cohort	Rugby (league players)	Recreational / amateur / military	175
Cox et al (2010)	n=20 (M=16, F=4)	35.2 ± 8.4	RCT	Half-marathon 21.1 km	Recreational / amateur / military	35
Cox et al (2010)[a]	n=20 (all male)	27.3 ± 6.4	RCT	Running	Recreational / amateur / military	98
Cox et al (2008)[¥]	n=70 (M=51; F=19)	19.3 ± 2.6	Prospective study	Mixed	Elite / professional / international / national	420
Cox et al (2004)	n=20 (all males)	24.6 ± 3.0	RCT	Distance Runners	Elite / professional / international / national	120
Cunniffe et al (2011)	n=31 (all male)	26.5	Prospective	Rugby	Elite / professional / international / national	336
Da Boit et al (2015)	n=17 (M=9, F=6)	28.3 ± 6.4	RCT	General	Recreational / amateur / military	112
Davison et al (2020)	n=61 (sex unknown)	39.3 ± 11.5	RCT	Endurance athletes	Recreational / amateur / military	90
Derman et al (2019)	n=567 (M=433, F=134)	32.1 ± 10.3	Prospective	Winter Paralympics	Elite / professional / international / national	12
Derman et al (2014)	n=3329 (sex not recorded)	Not recorded	Prospective	Paralympics	Elite / professional / international / national	14
Dressendorfer et al (2002)	n=9 (all males)	24.7 ± 2.1	Prospective	Mountain bike cyclists	Recreational / amateur / military	98
Edouard et al (2015)	n=528 (sex not recorded)	25.3 ± 4.2	Prospective	2013 European Athletics Indoors	Elite / professional / international / national	4

Supplementary Table A: Summary of articles: data extraction of the demographics

Edouard et al (2014)	n=1244 (sex not recorded)	Not recorded	Prospective	2012 European Athletics championships	Elite / professional / international / national	5
Edouard et al (2013)	n=440 (sex not recorded)	25.2 ± 4.0	Prospective	2011 European Athletics Indoors	Elite / professional / international / national	3
Fahlman and Engels (2005)	n=75 (all male)	20.5 ± 1.5	Prospective with athlete and control groups	American Football	Recreational / amateur / military	365
Fricker et al (2005)	n=20 (all males)	24.2 ± 3.1	Prospective	Middle-distance runners	Elite / professional / international / national	120
Furusawa et al (2007)	Racers n=21 (all male)	42.0 ± 1.74 (Mean ± SE)	Prospective cohort	Wheelchair marathon racers	Recreational / amateur	44
Gleeson et al (2012)[a]	n=80 (M=46, F=34)	22.5 ± 4.0	Prospective	Endurance-based physical activity	Recreational / amateur / military	120
Gleeson et al (2011)	n=26	25 ± 9	RCT	Endurance athletes	Recreational / amateur / military	120
Hall et al (2007)	n=14 (sex not recorded)	24.9 ± 5.8	RCT	Active adults	Recreational / amateur / military	28
Hanstad et al (2011)	n=99 (M=74, F=25)	Not recorded	Prospective	2010 Winter Olympics - Norwegian team	Elite / professional / international / national	19
Haywood et al (2014)	n=38 (all male)	24.7 ± 3.6	RCT	Rugby	Elite / professional / international / national	28
He et al (2014)	n=210 (M=147, F=63)	20.4 ± 1.9 (male) 20.5 ± 3.1 (female)	Prospective cohort	Endurance	Recreational / amateur / military	112
He et al (2013)[a]	n=31 (sex not recorded)	21 ± 2	Prospective cohort	Endurance	Recreational / amateur / military	112
He et al (2013)[b]	n=225 (sex not recorded)	21 ± 3	Prospective cohort	Endurance	Recreational / amateur / military	112
Henson et al (2008)	n=21 (M=18, F=3)	46.0 ± 2.3	RCT	Ultra marathon runner	Recreational / amateur / military	14
Ihalainen et al (2015)	n=25 (all male)	34.6 ± 1.3	Prospective cohort	Endurance	Recreational / amateur / military	84

Supplementary Table A: Summary of articles: data extraction of the demographics

Kekkonen et al (2007)	n=71 (M=63, F=8)	40 Range (23-69)	RCT	Marathon	Recreational / amateur / military	146
Laaksi et al (2007)	n=756 (all male) Control subjects (normal Vit D) n=628 (time loss recorded in this group)	Not recorded	Prospective cohort	Military	Recreational / amateur / military	184
McFarlin et al (2013)	n=35 (M=20, F=15)	35 ± 11	RCT	Marathon runners	Recreational / amateur / military	28
Michalickova et al (2016)	n=19 (M=14, F=5)	22.8 ± 2.5	RCT	Mixed	Elite / professional / international / national	98
Nehlsen-Cannarella et al (2000)	n=20 (all female)	22.6 + 0.5 (Mean ± SEM)	Prospective cohort	Rowers	Elite / professional / international / national	60
Nieman et al 2008	n=17 (all male)	25.0 ± 2.2 (Mean ± SE)	RCT	Cyclists	Recreational / amateur / military	35
Nordstrøm et al (2020)	n=225 (all male)	Mean 24 Range (17-41)	Prospective cohort study	Ice hockey	Elite / professional / international / national	210
Orhant et al (2010)¥	n=81 (all male)	Range (17–34)	Prospective cohort	Soccer	Elite / professional / international / national	1095
Orysiak et al (2017)	n=27 (all male)	16.5 ± 0.5	Prospective cohort	Ice hockey	Recreational / amateur / military	168
Pacque et al (2007)	n=17 (M=13, F=4)	41.5 ± 8.2	Prospective cohort	Ultra endurance running	Recreational / amateur / military	28
Peters et al (2004)	n=19 (all males); fast well trained runners (n=9), slow less trained runners (n=10)	35.4 ± 1.84 (fast well trained runners) 41.4 ± 2.77 (slow well trained runners) (Mean ± SEM)	Prospective cohort	Marathon runners	Recreational / amateur / military	14
Pyne et al (2001)	n=41 (M=21, F=20)	Range (15-27)	Prospective	Swimming	Elite / professional / international / national	42

Supplementary Table A: Summary of articles: data extraction of the demographics

Rama et al (2013)	n=19 (M=13, F=6)	17.2 ± 1.3 (male) 15.8 ± 0.8 (female)	Prospective cohort	Swimming	Elite / professional / international / national	203
Sawczuk et al (2020)	n=22 (M=16; F=6)	16.8 ± 0.5	Prospective longitudinal study	Mixed	Recreational / amateur / military	266
Schwellnus et al (2012)[¥]	n=259 (all male)	Not recorded	Prospective cohort	Rugby	Elite / professional / international / national	112
Soligard et al (2017)	n=11274 (M=6185, F= 5089)	Not recorded	Prospective cohort	Summer Olympics	Elite / professional / international / national	17
Somerville et al (2019)	n=12 (M=4, F=8)	16.5 ± 0.5	RCT	Hockey, football, netball	Recreational / amateur / military	63
Somerville et al (2019)[a]	Cohort 2 (school rugby) n=15; cohort 3 (school rugby) n=24, amateur n=18, total n=57 (all male)	Not recorded	Longitudinal cohort	Rugby	Recreational / amateur / military	273
Somerville et al (2019)[b]	Professional n=24 (all male)	Not recorded	Longitudinal cohort	Rugby	Elite / professional / international / national	273
Spence et al (2007)[¥]	n=63 (M=35, F=28)	22.5 ± 3.8 (elite) 25.2 ± 3.6 (recreational)	Prospective	Triathlon Cycling	Elite / professional / international / national	150
Steffen et al (2019)	n=3 984 (M=2002, F=1982)	Range (15-18)	Prospective cohort	Youth Summer Olympics	Elite / professional / international / national	13
Stephenson et al (2019)	n=7 (M=6 male, F=1)	30 ± 10	Prospective cohort	Para triathletes (mixed impairment)	Elite / professional / international / national	238
Svendsen et al (2016)	n=37 (M=22, F=17)	>18	Retrospective cohort	Cross country ski	Elite / professional / international / national	2889
Tiollier et al (2005)[¥]	n=21 (all male)	21 ± 2	Prospective cohort	Military	Recreational / amateur / military	33

Supplementary Table A: Summary of articles: data extraction of the demographics

Valtonen et al (2019¥	n=44 (M=31, F=13)	27 ± 6	Prospective observational study	Winter Olympics	Elite / professional / international / national	21
West et al (2011)	n=50 (M=33; F=17)	36.4 ± 8.9 (male) 35.6 ± 10.2 (female)	RCT	Cyclists and triathletes	Recreational / amateur / military	105

M: Males

F: Females

RCT: Randomised control trial

* All values are reported as mean + SD unless otherwise stated as range, mean ± SEM, mean ± SE or other as indicated

** In randomised control trails, only the placebo group was used for analysis

¥ Data extracted for subgroups in results table (Online Supplementary Table B)

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Author(s), Year	Classification			Outcomes						
	Method of diagnosis	**Pathological classification**	**Anatomical classification**	**Total number ARill/ARinf, number of ARill episodes or number of participants with ARill/ARinf**	**Time Loss ARill (>1 day) (n; %)**	**Days lost per ARill (days and mean ± SD)***	**Days lost (total days lost/ illness and total illnesses)**	**Symptom duration in days (mean ± SD or average) ***	**Duration of symptoms (days and number of athletes)**	**Other outcomes**
Alonso et al (2012)	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARill/ARinf	Total upper ARill n=49 Upper ARinf n=23	n=5 (5/23) 21% of upper ARinf					
Bjørneboe et al (2016)	Physician (diagnosis by history and clinical examination)	Undiagnosed ARill	General (upper/lower) ARill	ARill episodes n=1110						Illness burden 3.2 absence days/1000 player-days
Chesson et al (2020)	Self-reported symptoms only	Undiagnosed ARill	General (upper/lower) ARill	ARill n=15		Time loss (days) due to ARill n=12 days				Total days lost due to all illness n=19. Total days lost to ARill n=12 (63.2% of all time loss illnesses)
Cox et al (2010)	Self-reported symptoms with checklist and algorithm to diagnose infections	Undiagnosed ARill	Upper ARill	Upper ARill n=14				4.1 ± 3.7		

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Cox et al (2010)[a]	Self-reported symptoms with physician check (no examination)	Suspected ARinf	General (upper/lower) ARinf	ARinf episodes n=9				Mean 8 (Range not specified)	Total days all ARinf n=72	
Cox et al (2008)[a]	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARill/ARinf	All upper ARill episodes n=70 (confirmed upper ARinf pathogen identified n=21/70 (30%)				6.8 ± 3.8		50% of the athletes modified, 31% ceased all training, and 19% reduced their training volume or intensity
Cox et al (2008)[b]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Suspected upper ARinf (PCR negative but abnormal blood results) n=19/70 (27%)				6.1 ± 3.4		
Cox et al (2008)[c]	Physician (diagnosis by history and clinical examination)	Undiagnosed ARill	Upper ARill	Undiagnosed ARill n=30/70 (43%)				7.5 ± 3.4		
Cox et al (2004)	Self-reported symptoms with physician check (no examination)	Suspected ARinf	Upper ARinf	Upper ARinf n=6 in placebo month				Mean 5 Range (2-14)		

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Cunniffe et al (2011)	Self-reported symptoms with physician check (no examination)	Undiagnosed ARill	Upper ARill	Upper ARill n=123				Mean 4.7 Range (2-33)		In all ARill, 14% reported reduced activity, 8.6% felt need to go to bed
Da Boit et al (2015)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf n=8				2.79 ± 1.76		
Davison et al (2020)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Total upper ARinf n=130 episodes		Days lost 3.5 ± 5.0		10.4 ± 8.5		Reduced training 3.4 ± 5.1 (Mean ± SD)
Derman et al (2019)	Physician (diagnosis by history and clinical examination)	Undiagnosed ARill	General (upper/lower) ARill	All ARill n=28		Days lost n=9				
Derman et al (2014)	Physician (diagnosis by history and clinical examination)	Undiagnosed ARill	General (upper/lower) ARill	All ARill n=152	n=19 (19/152) 12.5% of all ARill					
Dressendorfer et al (2002)	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf n=4 (including 1 case influenza)	n=1 (influenza case) (1/5) 20% of upper ARinf	Influenza time loss days n=7 days; other upper ARinf time loss days n=0				

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Edouard et al (2015)	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf n=8	n=4 (4/8) 50% of all upper ARinf					
Edouard et al (2014)	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf n=9	n=4 (4/9) 44% of upper ARinf					Upper ARinf time loss n=4, all time-loss illness n=6 (66.7% of all time loss illnesses)
Edouard et al (2013)	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf n=8	n=1 (1/8) 12.5% of upper ARinf					
Fahlman and Engels (2005)	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf n=174				13.3 ± 3.6		
Fricker et al (2005)	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	15 athletes reported at least one episode of upper ARinf with mean number of episodes 2.5 (range 1-5)				Mean 8.3 Range (2-44)		

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Furusawa et al (2007)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Number of racers with ARinf symptoms n=8 ("throughout experiment") n=4 (post-race)						
Gleeson et al (2012)[a]	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	At least one week with upper ARinf n=50, ≥3 weeks with upper ARinf n=24				3.6 ± 1.0		
Gleeson et al (2011)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Number of ARinf episodes 2.1 ± 1.2 (Mean ± SD)				7.6 ± 3.2		
Hall et al (2007)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf n=7				8.6 ± 1.5 (Mean ± SE)		
Hanstad et al (2011)	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Total ARinf n=4; Infectious mononucleosis n=1, Upper ARinf n=3						n=1 did not compete, n=2 missed one competition, n=1 missed a relay for example

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Haywood et al (2014)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Players with upper ARinf symptoms n=19				6.7 ± 7.9		
He et al (2014)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf symptoms n=92				11.6 ± 6.8 (males) 15.5 ± 9.3 (females) Mean 13 (all)		
He et al (2013)[a]	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Number of ARinf episodes 1.0 ± 1.1 (Mean ± SD)				8.2 ± 4.0		
He et al (2013)[b]	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Participant with ≥ 1 episode of upper ARinf n=103				Mean 5 Range (5-7) (optimal Vit D n=3) Mean 8 Range (6-9) (adequate Vit D n=56) Mean 8 Range (5-14) (inadequate Vit D n=27) Mean 13 Range (10-17) (deficient Vit D n=12)		Training negatively affected in 70% of athletes with upper ARinf and training load reduced by an average of 24%.

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Henson et al (2008)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf n=5					Total sick days n=29 (for 5 ill athletes)	
Ihalainen et al (2015)	Self-reported symptoms only	Undiagnosed ARill	Upper ARill	Episodes of upper ARill symptoms n=19				11 ± 7		
Kekkonen et al (2007)	Self-reported symptoms only	Suspected ARinf	UpperARinf	Upper ARinf n=28				6.3 ± 4.3 (training group) 4.2 ± 2.2 (post-marathon group)		
Laaksi et al (2007)	Physician (diagnosis by history and clinical examination)	Suspected ARinf	General (upper/lower) ARinf			Median: 2; Q1-Q3: 0–4				
McFarlin et al (2013)	Self-reported symptoms only	Suspected ARinf	Upper ARinf					3.9 ± 0.2		
Michalickova et al (2016)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Athletes with upper ARinf n=11		Total days without training n=1.7 ± 2.3		10.6 ± 4.7	Infected days n=132 in 11 athletes	Proportion of athletes reporting impaired training 42%

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Nehlsen-Cannarella et al (2000)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf					5.2 ± 1.2 (Mean ± SE)		
Nieman et al 2008	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf n=6				3.7 ± 0.6 (Mean ± SE)		
Nordstrøm et al (2020)	Self-reported symptoms only	Undiagnosed ARill	General (upper/lower) ARill	All ARill n=151	n=53 (53/151) 35.1% of ARill		ARill total days lost n=280, total number of ARill n=151			Total days lost due to ARill n=280 (59.8% of all time loss illnesses)
Orhant et al (2010)[a]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf n=151	n=17 (17/151) 11.3% of all upper ARinf	Days lost n=34	Days lost per episode 2.0	Mean 3.1 (Range not specified)		
Orhant et al (2010)[b]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Lower ARinf	Lower ARinf n=4	n=2 (2/4) 50% of all lower ARinf	Days lost n=5	Days lost per episode 2.5	Mean 4.8 (Range not specified)		
Orysiak et al (2017)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf n=59				6.3 ± 4.6	Total symptom days n=427 in 27 athletes	

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Pacque et al (2007)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf: Pre-race n=4, post-race n=3				Average 8.5 (pre-race period) Average 6 (post-race period)	Total symptom days n=34 (pre-race) n=18 (post-race)	
Peters et al (2004)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf Fast well trained (FWT) n=5 Slow less trained (SLT) n=4				Average 4.3 (FWT) Average 3.5 (SLT)		
Pyne et al (2001)	Physician (diagnosis by history and clinical examination)	Undiagnosed ARill	General (upper/lower) ARill	ARill n=18				Median 4 Range (1-21)		
Rama et al (2013)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Episodes of upper ARinf n=31 in 19 athletes				6.7 ± 0.4		
Sawczuk et al (2020)	Self-reported symptoms only	Suspected ARinf	Upper ARinf	Upper ARinf episodes n=45				17 ± 18		
Schwellnus et al (2012)[a]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	General (upper/lower) ARinf	All ARinf n=98	Estimated time loss ARinf n=18 (18/98) 18.4% of all ARinf					

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Schwellnus et al (2012)[b]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARill/ARinf	Upper ARill n=72	Upper ARinf n=13 (13/72) 18.1% of upper ARill					
Soligard et al (2017)	Physician (diagnosis by history and clinical examination)	Undiagnosed ARill	General (upper/lower) ARill	All ARill n=292	ARill n=54 (54/292) 18.5% of all ARill					
Somerville et al (2019)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf n=12				Average 12.3		
Somerville et al (2019)[a]	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Number of subjects with ARinf in cohort 2 n=8, cohort 3 n=17, amateurs n=6				Mean upper ARinf duration per 1000 non-illness days 59.6 ± 183.2 (cohort 2) 522.1 ± 1138.8 (cohort 3) 64.3 ± 173.9 (amateurs)		
Somerville et al (2019)[b]	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Number of subject with ARinf in professional cohort n=12				Mean Upper ARinf duration per 1000 non-illness days 32.6 ± 59.7 (professionals)		

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Spence et al (2007)[a]	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	All athletes confirmed ARinf n=9				9.6 ± 2.4		Rhinovirus most common pathogen isolated. Symptom and functional impairment severity scores were higher in subjects with an infectious pathogen episode, particularly on illness days 3–4
Spence et al (2007)[b]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	All athletes suspected upper ARinf n=19				6.5 ± 3.2		
Steffen et al (2019)	Physician (diagnosis by history and clinical examination)	Undiagnosed ARill	General (upper/lower) ARill	All ARill n=168	n=37 (37/168) 22% of ARill					Time loss ARill n=37, all illness time loss n=66 (56.1% of all time loss illness)
Stephenson et al (2019)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Upper ARinf	Upper ARinf n=22						During 50% of upper ARinf episodes, athletes had to reduce or

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

										suspend training
Svendsen et al (2016)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	General (upper/lower) ARinf	All ARinf n=410				5 ± 4		
Tiollier et al (2005)[a]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf episodes n=16 (upper ARinf symptoms recorded n=30: rhinopharyngitis n=12/30 (40%)				7.6 ± 1.2 (Mean ± SEM)		
Tiollier et al (2005)[a]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf (tonsillitis) n=5/30 (17%)				8.2 ± 3.8 (Mean ± SEM)		
Tiollier et al (2005)[a]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf (sinusitis) n=4/30 (13%)				10.7 ± 4.8 (Mean ± SEM)		
Tiollier et al (2005)[a]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Upper ARinf	Upper ARinf (otitis media) n=3/30 (10%)				4.3 ± 0.9 (Mean ± SEM)		

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Tiollier et al (2005)[b]	Physician (diagnosis by history and clinical examination)	Suspected ARinf	Lower ARinf	Lower ARinf (bronchitis) n=6/30 (20%)				7.8 ± 2.3 (Mean ± SEM)		
Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	Upper ARinf (athletes with symptoms of "common cold") n=20				8.3 ± 7.8		Only one athlete lost competition on 1 day due to a respiratory infection
Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	Coronavirus 229E n=2				13.5 ± 16.3		
Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	Influenza B n=1				7.0		
Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	Respiratory syncytial virus (RSV) A n=4				8.7 ± 3.2		

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	UpperARinf	Rhinovirus n=1				2.0		
Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	Metapneumo virus n=4				4.0 ± 1.7		
Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	Coronavirus NL63 n=1				3.0		
Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	Coronavirus OC43 n=2				18.0 ± 11.3		
Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	Respiratory syncytial virus (RSV) B n=1				7.0		

Supplementary Table B: Summary of articles: data extraction by classification and outcomes

Valtonen et al (2019)	Physician diagnosis including pathology confirmed (PCR/culture/ serology)	Confirmed ARinf	Upper ARinf	lnfluenza A n=1				3.0		
West et al (2011)	Self-reported symptoms with checklist and algorithm to diagnose infections	Suspected ARinf	Lower ARinf					7.4 ± 10.3 (males) 5.1 ± 14.7 (females)		

ARill: Acute respiratory illness
ARinf: Acute respiratory infection
* Values are mean ± standard deviation (SD) unless stated differently

Online Supplementary Table C: Modified Downs and Black and Oxford Level of Evidence

Author(s), Year	Modified Downs and Black (score out of 13)	Oxford Level of Evidence
Alonso et al (2012)	12	2b
Bjørneboe et al (2016)	11	1b
Chesson et al (2020)	10	1b
Cox et al (2010)	11	1b
Cox et al (2010)[a]	11	1b
Cox et al (2008)	10	2b
Cox et al (2004)	10	1b
Cunniffe et al (2011)	11	2b
Da Boit et al (2015)	11	1b
Davison et al (2020)	10	2b
Derman et al (2019)	12	2b
Derman et al (2014)	12	2b
Dressendorfer et al (2002)	9	2b
Edouard et al (2015)	13	2b
Edouard et al (2014)	12	2b
Edouard et al (2013)	12	2b
Fahlman and Engels (2005)	12	2b
Fricker et al (2005)	10	2b
Furusawa et al (2007)	9	3b
Gleeson et al (2012)[a]	10	2b
Gleeson et al (2011)	10	1b
Hall et al (2007)	10	1b
Hanstad et al (2011)	12	2b
Haywood et al (2014)	10	1b

Online Supplementary Table C: Modified Downs and Black and Oxford Level of Evidence

He et al (2014)	10	1b
He et al (2013)[a]	11	1b
He et al (2013)[b]	11	2b
Henson et al (2008)	10	1b
Ihalainen et al (2015)	10	2b
Kekkonen et al (2007)	12	1b
Laaksi et al (2007)	12	1b
McFarlin et al (2013)	10	1b
Michalickova et al (2016)	9	1b
Nehlsen-Cannarella et al (2000)	11	2b
Nieman et al 2008	7	2b
Nordstrøm et al (2020)	12	2b
Orhant et al (2010)	8	2b
Orysiak et al (2017)	11	2b
Pacque et al (2007)	12	2b
Peters et al (2004)	10	2b
Pyne et al (2001)	12	2b
Rama et al (2013)	10	3b
Sawczuk et al (2020)	10	2b
Schwellnus et al (2012)	10	2b
Soligard et al (2017)	12	2b
Somerville et al (2019)	11	2b
Somerville et al (2019)[a]	10	2b
Spence et al (2007)	10	1b
Steffen et al (2019)	11	2b
Stephenson et al (2019)	10	3b

Online Supplementary Table C: Modified Downs and Black and Oxford Level of Evidence

Svendsen et al (2016)	11	2b
Tiollier et al (2005)	10	2b
Valtonen et al (2019)	12	1b
West et al (2011)	10	1b

Online Supplementary Table C: Modified Downs and Black and Oxford Level of Evidence

		Modified Downs and Black													
Author, year	Oxford Level of Evidence	Reporting Yes=1 No=0							External validity Yes = 1 No = 0 Unable to determine= 0		Internal validity - bias Yes = 1 No = 0 Unable to determine= 0			Internal validity - confounding (selection bias) Yes = 1 No = 0 Unable to determine= 0	
		Hypothesis / aim described	Main outcomes described	Characteristics of patients described	Main findings described	Estimates of the random variability	Characteristics of patients lost to follow-up	Actual probability values	Subjects recruited representative of the entire population	Subjects participating representative of the entire population	Data dredging reported (if applicable)	Statistical tests used	Outcome measures valid/ reliable	Losses of follow up taken into account	Total
Alonso et al (2012)	2b	1	1	0	1	1	1	1	1	1	1	1	1	1	12
Bjørneboe et al (2016)	1b	1	1	0	1	1	0	1	1	1	1	1	1	1	11
Chesson et al (2020)	1b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Cox et al (2010)	1b	1	1	1	1	1	1	1	0	0	1	1	1	1	11
Cox et al (2010)a	1b	1	1	1	1	1	1	1	0	0	1	1	1	1	11
Cox et al (2008)	2b	1	1	1	1	1	1	0	0	0	1	1	1	1	10
Cox et al (2004)	1b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Cunniffe et al (2011)	1b	1	1	0	1	1	1	0	1	1	1	1	1	1	11
Da Boit et al (2015)	1b	1	1	0	1	1	1	0	1	1	1	1	1	1	11

Online Supplementary Table C: Modified Downs and Black and Oxford Level of Evidence

Davison et al (2020)	2b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Derman et al (2019)	2b	1	1	1	1	1	1	0	1	1	1	1	1	1	12
Derman et al (2014)	2b	1	1	1	1	1	1	0	1	1	1	1	1	1	12
Dressendorfer et al (2002)	2b	1	1	0	1	1	1	0	0	0	1	1	1	1	9
Edouard et al (2015)	2b	1	1	1	1	1	1	1	1	1	1	1	1	1	13
Edouard et al (2014)	2b	1	1	0	1	1	1	1	1	1	1	1	1	1	12
Edouard et al (2013)	2b	1	1	0	1	1	1	1	1	1	1	1	1	1	12
Fahlman and Engels (2005)	2b	1	1	1	0	1	1	1	1	1	1	1	1	1	12
Fricker et al (2005)	2b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Furusawa et al (2007)	3b	1	1	0	1	1	1	0	0	0	1	1	1	1	9
Gleeson et al (2012)a	2b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Gleeson et al (2011)	1b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Hall et al (2007)	1b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Hanstad et al (2011)	2b	1	1	0	1	1	1	1	1	1	1	1	1	1	12
Haywood et al (2014)	1b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
He et al (2014)	1b	1	1	1	1	1	1	1	0	0	0	1	1	1	10
He et al (2013)a	1b	1	1	1	1	1	1	1	0	0	1	1	1	1	11

Online Supplementary Table C: Modified Downs and Black and Oxford Level of Evidence

He et al (2013)b	2b	1	1	1	1	1	1	1	0	0	1	1	1	1	11
Henson et al (2008)	1b	1	1	1	1	1	0	1	0	0	1	1	1	1	10
Ihalainen et al (2015)	2b	1	1	1	1	1	1	0	0	0	1	1	1	1	10
Kekkonen et al (2007)	1b	1	1	1	1	1	1	1	0	1	1	1	1	1	12
Laaksi et al (2007)	1b	1	1	0	1	1	1	1	1	1	1	1	1	1	12
McFarlin et al (2013)	1b	1	1	1	1	1	0	1	0	0	1	1	1	1	10
Michalickova et al (2016)	1b	1	1	1	1	1	0	1	0	0	1	1	1	0	9
Nehlsen-Cannarella et al (2000)	2b	1	1	1	1	1	1	1	0	0	1	1	1	1	11
Nieman et al (2008)	2b	1	1	0	0	1	0	1	0	0	1	1	1	0	7
Nordstrøm et al (2020)	2b	1	1	1	1	1	1	0	1	1	1	1	1	1	12
Orhant et al (2010)	2b	1	1	0	1	1	0	0	1	1	1	1	0	0	8
Orysiak et al (2017)	2b	1	1	1	1	1	1	1	0	0	1	1	1	1	11
Pacque et al (2007)	2b	1	1	1	1	1	1	1	1	1	0	1	1	1	12
Peters et al (2004)	2b	1	1	1	1	1	0	1	1	1	0	1	1	0	10
Pyne et al (2001)	2b	1	1	1	1	1	1	1	1	1	0	1	1	1	12
Rama et al (2013)	3b	1	1	1	1	1	1	1	0	0	0	1	1	1	10

Online Supplementary Table C: Modified Downs and Black and Oxford Level of Evidence

Sawczuk et al (2020)	2b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Schwellnus et al (2012)	2b	1	1	0	1	1	0	0	1	1	1	1	1	1	10
Soligard et al (2017)	2b	1	1	1	1	1	1	0	1	1	1	1	1	1	12
Somerville et al (2019)	2b	1	1	1	1	1	0	0	1	1	1	1	1	1	11
Somerville et al (2019)a	2b	1	1	1	1	1	0	1	0	0	1	1	1	1	10
Spence et al (2007)	1b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Steffen et al (2019)	2b	1	1	0	1	1	1	0	1	1	1	1	1	1	11
Stephenson et al (2019)	3b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Svendsen et al (2016)	1b	1	1	1	1	1	1	1	0	0	1	1	1	1	11
Tiollier et al (2005)a	2b	1	1	0	1	1	1	1	0	0	1	1	1	1	10
Valtonen et al (2019)	1b	1	1	0	1	1	1	1	1	1	1	1	1	1	12
West et al (2011)	1b	1	1	1	1	1	1	0	0	0	1	1	1	1	10

Online Supplementary Table C: Modified Downs and Black and Oxford Level of Evidence